pathway_name,pathway_id,pathway_url,gene_symbol,ensg_id,chembl_id,drug_name,phase,status,disease_id,disease_name,mechanismOfAction,smiles
TWIK related potassium channel (TREK),R-HSA-1299503,https://reactome.org/PathwayBrowser/#/R-HSA-1299503,KCNK10,ENSG00000100433,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
TWIK related potassium channel (TREK),R-HSA-1299503,https://reactome.org/PathwayBrowser/#/R-HSA-1299503,KCNK10,ENSG00000100433,CHEMBL1256,ISOFLURANE,3.0,Terminated,EFO_0011061,toxicity,,FC(F)OC(Cl)C(F)(F)F
TWIK related potassium channel (TREK),R-HSA-1299503,https://reactome.org/PathwayBrowser/#/R-HSA-1299503,KCNK10,ENSG00000100433,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
TWIK related potassium channel (TREK),R-HSA-1299503,https://reactome.org/PathwayBrowser/#/R-HSA-1299503,KCNK2,ENSG00000082482,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
TWIK related potassium channel (TREK),R-HSA-1299503,https://reactome.org/PathwayBrowser/#/R-HSA-1299503,KCNK2,ENSG00000082482,CHEMBL1256,ISOFLURANE,3.0,Recruiting,EFO_0009686,respiratory failure,,FC(F)OC(Cl)C(F)(F)F
TWIK related potassium channel (TREK),R-HSA-1299503,https://reactome.org/PathwayBrowser/#/R-HSA-1299503,KCNK2,ENSG00000082482,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK10,ENSG00000100433,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK10,ENSG00000100433,CHEMBL1256,ISOFLURANE,3.0,Terminated,EFO_0011061,toxicity,,FC(F)OC(Cl)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK10,ENSG00000100433,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK18,ENSG00000186795,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK18,ENSG00000186795,CHEMBL1256,ISOFLURANE,3.0,Withdrawn,HP_0000023,Inguinal hernia,,FC(F)OC(Cl)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK18,ENSG00000186795,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK2,ENSG00000082482,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK2,ENSG00000082482,CHEMBL1256,ISOFLURANE,3.0,Recruiting,EFO_0009686,respiratory failure,,FC(F)OC(Cl)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK2,ENSG00000082482,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK3,ENSG00000171303,CHEMBL1754,DOXAPRAM,4.0,,EFO_0000684,respiratory system disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK3,ENSG00000171303,CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,4.0,,EFO_0003818,lung disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK3,ENSG00000171303,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK3,ENSG00000171303,CHEMBL1256,ISOFLURANE,3.0,Recruiting,EFO_0009686,respiratory failure,,FC(F)OC(Cl)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK3,ENSG00000171303,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK9,ENSG00000169427,CHEMBL1754,DOXAPRAM,4.0,,EFO_0000684,respiratory system disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK9,ENSG00000169427,CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,4.0,,EFO_0003818,lung disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK9,ENSG00000169427,CHEMBL1200694,SEVOFLURANE,3.0,Not yet recruiting,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK9,ENSG00000169427,CHEMBL1256,ISOFLURANE,3.0,Withdrawn,HP_0000023,Inguinal hernia,,FC(F)OC(Cl)C(F)(F)F
Phase 4 - resting membrane potential,R-HSA-5576886,https://reactome.org/PathwayBrowser/#/R-HSA-5576886,KCNK9,ENSG00000169427,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP1,ENSG00000196611,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP1,ENSG00000196611,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP1,ENSG00000196611,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP1,ENSG00000196611,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0008903,lung cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP1,ENSG00000196611,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP1,ENSG00000196611,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL206815,APRATASTAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL440498,CTS-1027,2.0,Completed,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP13,ENSG00000137745,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP7,ENSG00000137673,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP7,ENSG00000137673,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP7,ENSG00000137673,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP7,ENSG00000137673,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0007254,breast cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP7,ENSG00000137673,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP8,ENSG00000118113,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP8,ENSG00000118113,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP8,ENSG00000118113,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP8,ENSG00000118113,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP8,ENSG00000118113,CHEMBL440498,CTS-1027,2.0,Terminated,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Collagen degradation,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,MMP8,ENSG00000118113,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP1,ENSG00000196611,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP1,ENSG00000196611,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP1,ENSG00000196611,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP1,ENSG00000196611,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0008903,lung cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP1,ENSG00000196611,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP1,ENSG00000196611,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL206815,APRATASTAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL440498,CTS-1027,2.0,Completed,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP13,ENSG00000137745,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP7,ENSG00000137673,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP7,ENSG00000137673,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP7,ENSG00000137673,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP7,ENSG00000137673,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0007254,breast cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP7,ENSG00000137673,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP8,ENSG00000118113,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP8,ENSG00000118113,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP8,ENSG00000118113,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP8,ENSG00000118113,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP8,ENSG00000118113,CHEMBL440498,CTS-1027,2.0,Terminated,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,MMP8,ENSG00000118113,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL877,TRANEXAMIC ACID,4.0,,HP_0000132,Menorrhagia,,NC[C@H]1CC[C@H](C(=O)O)CC1
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL2108147,STREPTOKINASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL2108250,ANISTREPLASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL1046,AMINOCAPROIC ACID,4.0,Unknown status,MP_0001914,hemorrhage,,NCCCCCC(=O)O
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL1201619,APROTININ,4.0,Completed,MP_0001914,hemorrhage,,
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL3707226,DEFIBROTIDE SODIUM,4.0,,MONDO_0019514,hepatic veno-occlusive disease,,
Degradation of the extracellular matrix,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,PLG,ENSG00000122194,CHEMBL2109084,DESMOTEPLASE,3.0,Completed,EFO_0000712,stroke,,
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP1,ENSG00000196611,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP1,ENSG00000196611,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP1,ENSG00000196611,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP1,ENSG00000196611,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0008903,lung cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP1,ENSG00000196611,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP1,ENSG00000196611,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL206815,APRATASTAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL440498,CTS-1027,2.0,Completed,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP13,ENSG00000137745,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP7,ENSG00000137673,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP7,ENSG00000137673,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP7,ENSG00000137673,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP7,ENSG00000137673,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0007254,breast cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP7,ENSG00000137673,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP8,ENSG00000118113,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP8,ENSG00000118113,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP8,ENSG00000118113,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP8,ENSG00000118113,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP8,ENSG00000118113,CHEMBL440498,CTS-1027,2.0,Terminated,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,MMP8,ENSG00000118113,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL877,TRANEXAMIC ACID,4.0,,HP_0000132,Menorrhagia,,NC[C@H]1CC[C@H](C(=O)O)CC1
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL2108147,STREPTOKINASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL2108250,ANISTREPLASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL1046,AMINOCAPROIC ACID,4.0,Unknown status,MP_0001914,hemorrhage,,NCCCCCC(=O)O
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL1201619,APROTININ,4.0,Completed,MP_0001914,hemorrhage,,
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL3707226,DEFIBROTIDE SODIUM,4.0,,MONDO_0019514,hepatic veno-occlusive disease,,
Activation of Matrix Metalloproteinases,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,PLG,ENSG00000122194,CHEMBL2109084,DESMOTEPLASE,3.0,Completed,EFO_0000712,stroke,,
Basigin interactions,,,MMP1,ENSG00000196611,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Basigin interactions,,,MMP1,ENSG00000196611,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Basigin interactions,,,MMP1,ENSG00000196611,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Basigin interactions,,,MMP1,ENSG00000196611,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0008903,lung cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Basigin interactions,,,MMP1,ENSG00000196611,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Basigin interactions,,,MMP1,ENSG00000196611,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,MMP1,ENSG00000196611,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,MMP1,ENSG00000196611,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,MMP1,ENSG00000196611,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,MMP1,ENSG00000196611,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0008903,lung cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,MMP1,ENSG00000196611,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,MMP1,ENSG00000196611,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL877,TRANEXAMIC ACID,4.0,,HP_0000132,Menorrhagia,,NC[C@H]1CC[C@H](C(=O)O)CC1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL2108147,STREPTOKINASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL2108250,ANISTREPLASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL1046,AMINOCAPROIC ACID,4.0,Unknown status,MP_0001914,hemorrhage,,NCCCCCC(=O)O
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL1201619,APROTININ,4.0,Completed,MP_0001914,hemorrhage,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL3707226,DEFIBROTIDE SODIUM,4.0,,MONDO_0019514,hepatic veno-occlusive disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,PLG,ENSG00000122194,CHEMBL2109084,DESMOTEPLASE,3.0,Completed,EFO_0000712,stroke,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201657,HEPARIN SODIUM,4.0,,EFO_0000275,atrial fibrillation,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201476,ENOXAPARIN SODIUM,4.0,,EFO_0000612,myocardial infarction,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1200644,FONDAPARINUX SODIUM,4.0,,EFO_0000612,myocardial infarction,,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201414,TINZAPARIN SODIUM,4.0,Completed,EFO_0003907,deep vein thrombosis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201460,DALTEPARIN SODIUM,4.0,,EFO_0004286,venous thromboembolism,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201202,FONDAPARINUX,4.0,,HP_0004419,Recurrent thrombophlebitis,,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201534,DANAPAROID SODIUM,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL4650299,HEPARIN,3.0,Completed,EFO_0000319,cardiovascular disease,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL2108080,PARNAPARIN SODIUM,3.0,Terminated,EFO_0000545,infertility,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL2108806,BEMIPARIN SODIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL2109204,NADROPARIN CALCIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL2108718,SEMULOPARIN SODIUM,3.0,Terminated,EFO_0004286,venous thromboembolism,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL4297754,FITUSIRAN,3.0,Completed,MONDO_0010602,hemophilia A,,
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-381426,https://reactome.org/PathwayBrowser/#/R-HSA-381426,SERPINC1,ENSG00000117601,CHEMBL1201513,HEPARIN CALCIUM,2.0,Completed,EFO_1000954,habitual abortion,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL1743034,IXEKIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL1743068,SECUKINUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL4297700,BIMEKIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL4298102,VUNAKIZUMAB,3.0,Not yet recruiting,EFO_0000676,psoriasis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL4298023,M-1095,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL4297686,IZOKIBEP,3.0,"Active, not recruiting",EFO_1000710,hidradenitis suppurativa,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL3990000,TIBULIZUMAB,2.0,Withdrawn,EFO_0000699,Sjogren syndrome,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL4297926,CJM-112,2.0,Completed,EFO_0003894,acne,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL17A,ENSG00000112115,CHEMBL2109470,PERAKIZUMAB,1.0,Completed,EFO_0003778,psoriatic arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6R,ENSG00000160712,CHEMBL2108730,SARILUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6R,ENSG00000160712,CHEMBL3833307,SATRALIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6R,ENSG00000160712,CHEMBL1237022,TOCILIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6R,ENSG00000160712,CHEMBL4650406,LEVILIMAB,3.0,"Active, not recruiting",EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,IL6R,ENSG00000160712,CHEMBL3833343,VOBARILIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,MMP1,ENSG00000196611,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,MMP1,ENSG00000196611,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,MMP1,ENSG00000196611,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,MMP1,ENSG00000196611,CHEMBL279785,MARIMASTAT,3.0,Completed,MONDO_0008903,lung cancer,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,MMP1,ENSG00000196611,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,MMP1,ENSG00000196611,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2159122,ELUXADOLINE,4.0,,EFO_0000555,irritable bowel syndrome,,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL596,FENTANYL,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL607,MEPERIDINE,4.0,,EFO_0003843,pain,,CCOC(=O)C1(c2ccccc2)CCN(C)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL651,METHADONE,4.0,,EFO_0003843,pain,,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL656,OXYCODONE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL688,FENTANYL CITRATE,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL70,MORPHINE,4.0,Completed,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL895,NALBUPHINE,4.0,Unknown status,EFO_0003843,pain,,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1200794,OXYMORPHONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1200825,METHADONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1200890,OXYCODONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201132,NALBUPHINE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201149,NALTREXONE HYDROCHLORIDE,4.0,Terminated,EFO_0003843,pain,,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201163,SUFENTANIL CITRATE,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1237044,TRAMADOL,4.0,Recruiting,EFO_0003843,pain,,COc1cccc(C2(O)CCCCC2CN(C)C)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1237055,HYDROMORPHONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1237065,TRAMADOL HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1237104,PROPOXYPHENE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1595,DIHYDROCODEINE,4.0,Completed,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1685,DEZOCINE,4.0,,EFO_0003843,pain,,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1701,MEPERIDINE HYDROCHLORIDE,4.0,Unknown status,EFO_0003843,pain,,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1718,NALOXONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2062266,DIHYDROCODEINE BITARTRATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2103744,MORPHINE SULFATE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2219416,NALOXEGOL OXALATE,4.0,,EFO_0003843,pain,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2443262,OLICERIDINE,4.0,,EFO_0003843,pain,,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3137310,BENZHYDROCODONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3833389,DEXTROMORAMIDE,4.0,,EFO_0003843,pain,,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL398707,HYDROMORPHONE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3989677,HYDROCODONE BITARTRATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL4297091,CODEINE SULFATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL485,CODEINE,4.0,Unknown status,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL511142,BUPRENORPHINE,4.0,Completed,EFO_0003843,pain,,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201099,CODEINE PHOSPHATE,4.0,,EFO_0003890,drug dependence,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2368861,BUPRENORPHINE HYDROCHLORIDE,4.0,,EFO_0003890,drug dependence,,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201770,METHYLNALTREXONE BROMIDE,4.0,,EFO_0005611,opioid dependence,,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1514,LEVOMETHADYL ACETATE,4.0,,EFO_0005611,opioid dependence,,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201776,TAPENTADOL,4.0,,EFO_0003843,pain,,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201777,TAPENTADOL HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1213351,PROPOXYPHENE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL963,OXYMORPHONE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3039508,NALDEMEDINE TOSYLATE,4.0,,EFO_0003843,pain,,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL314437,MEPTAZINOL,4.0,,EFO_0003843,pain,,CCC1(c2cccc(O)c2)CCCCN(C)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL33986,BUTORPHANOL,4.0,,EFO_0003843,pain,,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3989716,PROPOXYPHENE NAPSYLATE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3989826,OXYCODONE TEREPHTHALATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL299400,BUTORPHANOL TARTRATE,4.0,,EFO_0003890,drug dependence,,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL5315056,NALOXONE HYDROCHLORIDE DIHYDRATE,4.0,,EFO_0005611,opioid dependence,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2219418,NALOXEGOL,4.0,Terminated,HP_0002019,Constipation,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL270190,ALVIMOPAN,4.0,,HP_0002019,Constipation,,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL80,NALOXONE,4.0,,HP_0002019,Constipation,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1707,LOPERAMIDE HYDROCHLORIDE,4.0,Completed,HP_0002014,Diarrhea,,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2105749,SAMIDORPHAN L-MALATE,4.0,,EFO_0009963,bipolar I disorder,,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2105755,NALDEMEDINE,4.0,,HP_0002019,Constipation,,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1457,HYDROCODONE,4.0,,HP_0012735,Cough,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL19019,NALTREXONE,4.0,Completed,MONDO_0002046,alcohol abuse,,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL5315055,NALMEFENE HYDROCHLORIDE DIHYDRATE,4.0,,MONDO_0007079,alcohol dependence,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL982,NALMEFENE,4.0,Terminated,MONDO_0007079,alcohol dependence,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL658,SUFENTANIL,3.0,Completed,EFO_0000546,injury,,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1005,REMIFENTANIL,3.0,Completed,EFO_0000616,neoplasm,,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1186579,METHYLNALTREXONE,3.0,Withdrawn,EFO_0002618,pancreatic carcinoma,,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL841,LOPERAMIDE,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2364605,CEBRANOPADOL,3.0,Not yet recruiting,EFO_0003843,pain,,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL459324,DIACETYLMORPHINE,3.0,Completed,EFO_0005611,opioid dependence,,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201159,FENTANYL HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3039511,BEVENOPRAN,3.0,Terminated,HP_0002019,Constipation,,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL4297632,OXYCODEGOL,3.0,Completed,HP_0003419,Low back pain,,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1200665,DIPHENOXYLATE HYDROCHLORIDE,2.0,Completed,EFO_0000304,breast adenocarcinoma,,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL1201294,DIPHENOXYLATE,2.0,Completed,EFO_0000304,breast adenocarcinoma,,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL4594402,ORP-101,2.0,Completed,EFO_0000555,irritable bowel syndrome,,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL4297383,GSK-1521498,2.0,Completed,EFO_0001073,obesity,,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3219616,CP-866087,2.0,Completed,EFO_0001073,obesity,,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2103829,FAXELADOL,2.0,Completed,EFO_0005687,fibromyalgia,,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL426084,SAMIDORPHAN,2.0,Completed,EFO_0005203,eating disorder,,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2364619,METHYLSAMIDORPHAN,2.0,Completed,HP_0002019,Constipation,,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3137313,AXELOPRAN,2.0,Completed,HP_0002019,Constipation,,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL3989680,AXOMADOL,2.0,Completed,HP_0003419,Low back pain,,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL2103878,ODELEPRAN,2.0,Completed,MONDO_0007079,alcohol dependence,,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,OPRM1,ENSG00000112038,CHEMBL592,LEVORPHANOL,0.5,"Active, not recruiting",EFO_0003843,pain,,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1201580,ADALIMUMAB,4.0,Completed,EFO_0000384,Crohn's disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1201581,INFLIXIMAB,4.0,,EFO_0000384,Crohn's disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1201831,CERTOLIZUMAB PEGOL,4.0,,EFO_0000384,Crohn's disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1201572,ETANERCEPT,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1201833,GOLIMUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL2107911,ONERCEPT,3.0,Terminated,EFO_0003778,psoriatic arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL2108887,AFELIMOMAB,2.0,,EFO_0000540,immune system disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1743057,PEGSUNERCEPT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL1743054,OZORALIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL2108739,PLACULUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TNF,ENSG00000232810,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1519,TRANDOLAPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL419213,LISINOPRIL,4.0,,EFO_0000319,cardiovascular disease,,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL431,SPIRAPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL515606,CILAZAPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1165,MOEXIPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1168,RAMIPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1560,CAPTOPRIL,4.0,,EFO_0000319,cardiovascular disease,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1581,PERINDOPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1592,QUINAPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL3039598,FOSINOPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL317094,IMIDAPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL578,ENALAPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL838,BENAZEPRIL,4.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1200659,ENALAPRIL MALEATE,4.0,,EFO_0000373,congestive heart failure,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1694,BENAZEPRIL HYDROCHLORIDE,4.0,,EFO_0000400,diabetes mellitus,,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1201011,QUINAPRIL HYDROCHLORIDE,4.0,,EFO_0000400,diabetes mellitus,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1200343,PERINDOPRIL ERBUMINE,4.0,,EFO_0000537,hypertension,,CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1200534,MOEXIPRIL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL3039596,FOSINOPRIL SODIUM,4.0,,EFO_0000537,hypertension,,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+]
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL3544986,PERINDOPRIL ARGININE,4.0,,EFO_0000537,hypertension,,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL1237,LISINOPRIL ANHYDROUS,3.0,Withdrawn,EFO_0000319,cardiovascular disease,,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL589583,DELAPRIL,3.0,,EFO_0000319,cardiovascular disease,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL3989406,ENALAPRILAT,3.0,Completed,EFO_0000407,dilated cardiomyopathy,,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL577,ENALAPRILAT ANHYDROUS,3.0,Completed,EFO_0000407,dilated cardiomyopathy,,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,https://reactome.org/PathwayBrowser/#/R-HSA-2022377,ACE,ENSG00000159640,CHEMBL3187812,ILEPATRIL,2.0,Completed,EFO_0000537,hypertension,,CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL877,TRANEXAMIC ACID,4.0,,HP_0000132,Menorrhagia,,NC[C@H]1CC[C@H](C(=O)O)CC1
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL2108147,STREPTOKINASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL2108250,ANISTREPLASE,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL1046,AMINOCAPROIC ACID,4.0,Unknown status,MP_0001914,hemorrhage,,NCCCCCC(=O)O
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL1201619,APROTININ,4.0,Completed,MP_0001914,hemorrhage,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL3707226,DEFIBROTIDE SODIUM,4.0,,MONDO_0019514,hepatic veno-occlusive disease,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,PLG,ENSG00000122194,CHEMBL2109084,DESMOTEPLASE,3.0,Completed,EFO_0000712,stroke,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
Platelet degranulation,R-HSA-114608,https://reactome.org/PathwayBrowser/#/R-HSA-114608,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
Regulation of gene expression by Hypoxia-inducible Factor,R-HSA-1234158,https://reactome.org/PathwayBrowser/#/R-HSA-1234158,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
Signaling by VEGF,R-HSA-194138,https://reactome.org/PathwayBrowser/#/R-HSA-194138,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
VEGF ligand-receptor interactions,R-HSA-194313,https://reactome.org/PathwayBrowser/#/R-HSA-194313,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1421,DASATINIB,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000616,neoplasm,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Unknown status,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2109325,AMG-191,1.0,Recruiting,MONDO_0015974,severe combined immunodeficiency,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL1873475,IBRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3707348,ACALABRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4594293,ACALABRUTINIB MALEATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3936761,ZANUBRUTINIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL5314649,RITLECITINIB TOSYLATE,4.0,,EFO_0004192,alopecia areata,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4650485,PIRTOBRUTINIB,4.0,,EFO_1001469,Mantle cell lymphoma,,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4650321,ORELABRUTINIB,3.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4065122,FENEBRUTINIB,3.0,"Active, not recruiting",EFO_0003840,chronic progressive multiple sclerosis,,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4297865,ABIVERTINIB,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4085457,RITLECITINIB,3.0,Recruiting,EFO_0004208,Vitiligo,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4297866,ABIVERTINIB MALEATE,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4650323,TOLEBRUTINIB,3.0,Recruiting,EFO_0008520,primary progressive multiple sclerosis,,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3702854,RILZABRUTINIB,3.0,Recruiting,EFO_0007160,autoimmune thrombocytopenic purpura,,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4072833,EVOBRUTINIB,3.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4650338,EDRALBRUTINIB,2.0,Recruiting,EFO_0000096,neoplasm of mature B-cells,,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4071161,TIRABRUTINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3301600,SPEBRUTINIB BESYLATE,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3301625,SPEBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4163691,POSELTINIB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3900554,BMS-986142,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4594348,ELSUBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL4297674,BRANEBRUTINIB,1.0,Completed,EFO_0000685,rheumatoid arthritis,,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,BTK,ENSG00000010671,CHEMBL3545193,MSC-2364447,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,CYSLTR1,ENSG00000173198,CHEMBL787,MONTELUKAST,4.0,Unknown status,EFO_0003956,seasonal allergic rhinitis,,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,CYSLTR1,ENSG00000173198,CHEMBL1200681,MONTELUKAST SODIUM,4.0,,EFO_0005854,allergic rhinitis,,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,CYSLTR1,ENSG00000173198,CHEMBL603,ZAFIRLUKAST,4.0,,HP_0006536,Airway obstruction,,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,CYSLTR1,ENSG00000173198,CHEMBL21333,PRANLUKAST,3.0,Completed,EFO_0003956,seasonal allergic rhinitis,,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL2364653,ANIFROLUMAB,4.0,,EFO_0000540,immune system disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL1201558,INTERFERON ALFA-2B,4.0,,EFO_0000558,Kaposi's sarcoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL1201557,INTERFERON ALFACON-1,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL1201561,PEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL1201562,INTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL1201560,PEGINTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL1201563,INTERFERON BETA-1B,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL2108508,INTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL2108677,PEGINTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL4297819,ROPEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL2107842,ALBINTERFERON ALFA-2B,3.0,,EFO_0000616,neoplasm,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IFNAR1,ENSG00000142166,CHEMBL2109047,INTERFERON ALFA-N3,2.0,Completed,EFO_0000694,severe acute respiratory syndrome,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL1R1,ENSG00000115594,CHEMBL1201570,ANAKINRA,4.0,,EFO_0000540,immune system disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL1R1,ENSG00000115594,CHEMBL2109458,AMG-108,2.0,Withdrawn,EFO_0000400,diabetes mellitus,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL1R1,ENSG00000115594,CHEMBL2109607,MEDI-8968,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL6R,ENSG00000160712,CHEMBL2108730,SARILUMAB,4.0,,EFO_0000540,immune system disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL6R,ENSG00000160712,CHEMBL3833307,SATRALIZUMAB,4.0,,EFO_0000540,immune system disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL6R,ENSG00000160712,CHEMBL1237022,TOCILIZUMAB,4.0,,EFO_0000540,immune system disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL6R,ENSG00000160712,CHEMBL4650406,LEVILIMAB,3.0,"Active, not recruiting",EFO_0000685,rheumatoid arthritis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,IL6R,ENSG00000160712,CHEMBL3833343,VOBARILIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297564,COBITOLIMOD,3.0,Completed,EFO_0000729,ulcerative colitis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL2103792,AGATOLIMOD,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297838,TILSOTOLIMOD,3.0,Terminated,EFO_0002617,metastatic melanoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL2103793,AGATOLIMOD SODIUM,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297680,1018 ISS,3.0,Terminated,MONDO_0100096,COVID-19,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297776,LEFITOLIMOD,2.0,Completed,EFO_0000180,HIV-1 infection,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297993,EMD-1201081,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TLR9,ENSG00000239732,CHEMBL4297994,TILSOTOLIMOD SODIUM,2.0,Completed,EFO_0002617,metastatic melanoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL1201583,BEVACIZUMAB,4.0,Completed,EFO_0000305,breast carcinoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL1742982,AFLIBERCEPT,4.0,,EFO_0000365,colorectal adenocarcinoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL1201825,RANIBIZUMAB,4.0,,EFO_0003770,diabetic retinopathy,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL3707357,BROLUCIZUMAB,4.0,Withdrawn,EFO_0004683,wet macular degeneration,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL4297750,FARICIMAB,4.0,,EFO_0010977,macrovascular complications of diabetes,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL1201421,PEGAPTANIB SODIUM,4.0,,EFO_0004683,wet macular degeneration,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL4297163,MUPARFOSTAT,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL2108313,CONBERCEPT,3.0,Terminated,EFO_0001365,age-related macular degeneration,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL2110581,BEVASIRANIB,3.0,Withdrawn,EFO_0001365,age-related macular degeneration,,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL4297684,ABICIPAR PEGOL,3.0,,EFO_0005753,ocular vascular disease,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL2108752,PEGAPTANIB OCTASODIUM,3.0,Completed,MONDO_0810000,choroidal neovascularization,,
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,VEGFA,ENSG00000112715,CHEMBL3545259,VANUCIZUMAB,2.0,Terminated,MONDO_0005575,colorectal cancer,,
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200914,TAMSULOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL24778,SILODOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL611,TERAZOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL836,TAMSULOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201212,MIDODRINE,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc(OC)c(C(O)CNC(=O)CN)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201319,METARAMINOL,4.0,,EFO_0000319,cardiovascular disease,,C[C@H](N)[C@H](O)c1cccc(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL524,METHOXAMINE,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc(OC)c(C(O)C(C)N)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200561,DOXAZOSIN MESYLATE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1723,ALFUZOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL3989562,TERAZOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL709,ALFUZOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1215,PHENYLEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1cccc(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL723,CARVEDILOL,4.0,,EFO_0000319,cardiovascular disease,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1558,PRAZOSIN HYDROCHLORIDE,4.0,,EFO_0000400,diabetes mellitus,,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201167,CARVEDILOL PHOSPHATE,4.0,,EFO_0000537,hypertension,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2,PRAZOSIN,4.0,,EFO_0000537,hypertension,,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL707,DOXAZOSIN,4.0,Unknown status,EFO_0000537,hypertension,,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201044,DAPIPRAZOLE HYDROCHLORIDE,4.0,,EFO_0004190,open-angle glaucoma,,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200339,PHENYLEPHRINE HYDROCHLORIDE,4.0,,EFO_0006834,septic shock,,CNC[C@H](O)c1cccc(O)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0007214,common cold,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL12713,SERTINDOLE,4.0,,EFO_0005407,psychosis,,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2062264,PHENYLEPHRINE BITARTRATE,4.0,,EFO_0007214,common cold,,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL61006,PHENYLPROPANOLAMINE,4.0,,HP_0001742,Nasal congestion,,CC(N)C(O)c1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201216,DAPIPRAZOLE,4.0,,MONDO_0005041,glaucoma,,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL644,TRIMIPRAMINE,4.0,,MONDO_0002009,major depressive disorder,,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1200461,MIDODRINE HYDROCHLORIDE,3.0,Terminated,EFO_0006834,septic shock,,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2107546,BUCINDOLOL HYDROCHLORIDE,2.0,Completed,EFO_0000275,atrial fibrillation,,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL321582,BUCINDOLOL,2.0,Completed,EFO_0000275,atrial fibrillation,,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1197051,ISOXSUPRINE,2.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL1201103,METHOXAMINE HYDROCHLORIDE,2.0,Completed,EFO_0009523,fecal incontinence,,COc1ccc(OC)c(C(O)C(C)N)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL2104986,TEDATIOXETINE,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA1A,ENSG00000120907,CHEMBL559180,ISOXSUPRINE HYDROCHLORIDE,1.0,Completed,MONDO_0005301,multiple sclerosis,,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2A,ENSG00000150594,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
Adrenoceptors,R-HSA-390696,https://reactome.org/PathwayBrowser/#/R-HSA-390696,ADRA2B,ENSG00000274286,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2A,ENSG00000150594,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
Adrenaline signalling through Alpha-2 adrenergic receptor,R-HSA-392023,https://reactome.org/PathwayBrowser/#/R-HSA-392023,ADRA2B,ENSG00000274286,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
"Adrenaline,noradrenaline inhibits insulin secretion",R-HSA-400042,https://reactome.org/PathwayBrowser/#/R-HSA-400042,ADRA2A,ENSG00000150594,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2A,ENSG00000150594,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,ADRA2B,ENSG00000274286,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL1201828,ECULIZUMAB,4.0,,EFO_0000540,immune system disease,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL3989986,RAVULIZUMAB,4.0,,EFO_0000540,immune system disease,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL5315048,ZILUCOPLAN SODIUM,4.0,,EFO_0004991,Myasthenia gravis,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL4298086,POZELIMAB,4.0,,HP_0002243,Protein-losing enteropathy,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL2107979,PEXELIZUMAB,3.0,Completed,EFO_0001645,coronary artery disease,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL4298207,ZILUCOPLAN,3.0,Completed,EFO_0004991,Myasthenia gravis,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL4594316,CROVALIMAB,3.0,Withdrawn,EFO_0007292,Guillain-Barre syndrome,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL4297722,CEMDISIRAN,3.0,Recruiting,EFO_0004991,Myasthenia gravis,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL4297928,NOMACOPAN,3.0,Withdrawn,EFO_0007187,bullous pemphigoid,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL2109636,VILOBELIMAB,3.0,Recruiting,HP_0000999,Pyoderma,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL4298012,TESIDOLUMAB,2.0,Completed,EFO_0001365,age-related macular degeneration,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,C5,ENSG00000106804,CHEMBL3990025,OLENDALIZUMAB,2.0,Terminated,EFO_0002689,antiphospholipid syndrome,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL3545221,AZD2423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL3707228,PLOZALIZUMAB,2.0,Withdrawn,EFO_0000319,cardiovascular disease,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL2178573,ILACIRNON,2.0,Completed,EFO_0000401,diabetic nephropathy,,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL4297538,MK-0812,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL4650501,PF-4136309,2.0,Terminated,EFO_0004220,chronic hepatitis C virus infection,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL4457723,BMS-741672,2.0,Completed,EFO_0005762,neuropathic pain,,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR2,ENSG00000121807,CHEMBL2204263,JNJ-41443532,2.0,Completed,MONDO_0005148,type 2 diabetes mellitus,,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL1201187,MARAVIROC,4.0,Completed,EFO_0000180,HIV-1 infection,,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL1255794,APLAVIROC,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL1668019,APLAVIROC HYDROCHLORIDE,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL82301,VICRIVIROC,3.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL2109343,LERONLIMAB,3.0,Suspended,MONDO_0100096,COVID-19,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL1951914,AZD5672,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL1649931,PF-232798,2.0,Completed,EFO_0000764,HIV infection,,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL2107384,VICRIVIROC MALEATE,2.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL1688243,INCB-9471,2.0,Completed,EFO_0000764,HIV infection,,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL2109342,HGS-1025,1.0,Withdrawn,EFO_0000729,ulcerative colitis,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,CCR5,ENSG00000160791,CHEMBL2109341,CCR5MAB004,1.0,Completed,EFO_0000764,HIV infection,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2159122,ELUXADOLINE,4.0,,EFO_0000555,irritable bowel syndrome,,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL596,FENTANYL,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL607,MEPERIDINE,4.0,,EFO_0003843,pain,,CCOC(=O)C1(c2ccccc2)CCN(C)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL651,METHADONE,4.0,,EFO_0003843,pain,,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL656,OXYCODONE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL688,FENTANYL CITRATE,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL70,MORPHINE,4.0,Completed,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL895,NALBUPHINE,4.0,Unknown status,EFO_0003843,pain,,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1200794,OXYMORPHONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1200825,METHADONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1200890,OXYCODONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201132,NALBUPHINE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201149,NALTREXONE HYDROCHLORIDE,4.0,Terminated,EFO_0003843,pain,,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201163,SUFENTANIL CITRATE,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1237044,TRAMADOL,4.0,Recruiting,EFO_0003843,pain,,COc1cccc(C2(O)CCCCC2CN(C)C)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1237055,HYDROMORPHONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1237065,TRAMADOL HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1237104,PROPOXYPHENE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1595,DIHYDROCODEINE,4.0,Completed,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1685,DEZOCINE,4.0,,EFO_0003843,pain,,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1701,MEPERIDINE HYDROCHLORIDE,4.0,Unknown status,EFO_0003843,pain,,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1718,NALOXONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2062266,DIHYDROCODEINE BITARTRATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2103744,MORPHINE SULFATE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2219416,NALOXEGOL OXALATE,4.0,,EFO_0003843,pain,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2443262,OLICERIDINE,4.0,,EFO_0003843,pain,,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3137310,BENZHYDROCODONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3833389,DEXTROMORAMIDE,4.0,,EFO_0003843,pain,,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL398707,HYDROMORPHONE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3989677,HYDROCODONE BITARTRATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL4297091,CODEINE SULFATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL485,CODEINE,4.0,Unknown status,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL511142,BUPRENORPHINE,4.0,Completed,EFO_0003843,pain,,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201099,CODEINE PHOSPHATE,4.0,,EFO_0003890,drug dependence,,
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2368861,BUPRENORPHINE HYDROCHLORIDE,4.0,,EFO_0003890,drug dependence,,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201770,METHYLNALTREXONE BROMIDE,4.0,,EFO_0005611,opioid dependence,,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1514,LEVOMETHADYL ACETATE,4.0,,EFO_0005611,opioid dependence,,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201776,TAPENTADOL,4.0,,EFO_0003843,pain,,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201777,TAPENTADOL HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1213351,PROPOXYPHENE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL963,OXYMORPHONE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3039508,NALDEMEDINE TOSYLATE,4.0,,EFO_0003843,pain,,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL314437,MEPTAZINOL,4.0,,EFO_0003843,pain,,CCC1(c2cccc(O)c2)CCCCN(C)C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL33986,BUTORPHANOL,4.0,,EFO_0003843,pain,,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3989716,PROPOXYPHENE NAPSYLATE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3989826,OXYCODONE TEREPHTHALATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL299400,BUTORPHANOL TARTRATE,4.0,,EFO_0003890,drug dependence,,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL5315056,NALOXONE HYDROCHLORIDE DIHYDRATE,4.0,,EFO_0005611,opioid dependence,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2219418,NALOXEGOL,4.0,Terminated,HP_0002019,Constipation,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL270190,ALVIMOPAN,4.0,,HP_0002019,Constipation,,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL80,NALOXONE,4.0,,HP_0002019,Constipation,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1707,LOPERAMIDE HYDROCHLORIDE,4.0,Completed,HP_0002014,Diarrhea,,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2105749,SAMIDORPHAN L-MALATE,4.0,,EFO_0009963,bipolar I disorder,,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2105755,NALDEMEDINE,4.0,,HP_0002019,Constipation,,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1457,HYDROCODONE,4.0,,HP_0012735,Cough,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL19019,NALTREXONE,4.0,Completed,MONDO_0002046,alcohol abuse,,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL5315055,NALMEFENE HYDROCHLORIDE DIHYDRATE,4.0,,MONDO_0007079,alcohol dependence,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL982,NALMEFENE,4.0,Terminated,MONDO_0007079,alcohol dependence,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL658,SUFENTANIL,3.0,Completed,EFO_0000546,injury,,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1005,REMIFENTANIL,3.0,Completed,EFO_0000616,neoplasm,,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1186579,METHYLNALTREXONE,3.0,Withdrawn,EFO_0002618,pancreatic carcinoma,,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL841,LOPERAMIDE,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2364605,CEBRANOPADOL,3.0,Not yet recruiting,EFO_0003843,pain,,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL459324,DIACETYLMORPHINE,3.0,Completed,EFO_0005611,opioid dependence,,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201159,FENTANYL HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3039511,BEVENOPRAN,3.0,Terminated,HP_0002019,Constipation,,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL4297632,OXYCODEGOL,3.0,Completed,HP_0003419,Low back pain,,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1200665,DIPHENOXYLATE HYDROCHLORIDE,2.0,Completed,EFO_0000304,breast adenocarcinoma,,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL1201294,DIPHENOXYLATE,2.0,Completed,EFO_0000304,breast adenocarcinoma,,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL4594402,ORP-101,2.0,Completed,EFO_0000555,irritable bowel syndrome,,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL4297383,GSK-1521498,2.0,Completed,EFO_0001073,obesity,,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3219616,CP-866087,2.0,Completed,EFO_0001073,obesity,,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2103829,FAXELADOL,2.0,Completed,EFO_0005687,fibromyalgia,,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL426084,SAMIDORPHAN,2.0,Completed,EFO_0005203,eating disorder,,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2364619,METHYLSAMIDORPHAN,2.0,Completed,HP_0002019,Constipation,,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3137313,AXELOPRAN,2.0,Completed,HP_0002019,Constipation,,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL3989680,AXOMADOL,2.0,Completed,HP_0003419,Low back pain,,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL2103878,ODELEPRAN,2.0,Completed,MONDO_0007079,alcohol dependence,,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,OPRM1,ENSG00000112038,CHEMBL592,LEVORPHANOL,0.5,"Active, not recruiting",EFO_0003843,pain,,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1083385,CLOPIDOGREL BISULFATE,4.0,,EFO_0000556,ischemia,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1097279,CANGRELOR TETRASODIUM,4.0,,EFO_0000612,myocardial infarction,,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+]
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1201773,PRASUGREL HYDROCHLORIDE,4.0,,EFO_0000612,myocardial infarction,,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL398435,TICAGRELOR,4.0,Unknown status,EFO_0000612,myocardial infarction,,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1717,TICLOPIDINE HYDROCHLORIDE,4.0,,EFO_0000712,stroke,,Cl.Clc1ccccc1CN1CCc2sccc2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1771,CLOPIDOGREL,4.0,,HP_0004419,Recurrent thrombophlebitis,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL833,TICLOPIDINE,4.0,,HP_0004419,Recurrent thrombophlebitis,,Clc1ccccc1CN1CCc2sccc2C1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1201772,PRASUGREL,3.0,Completed,EFO_0000275,atrial fibrillation,,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL334966,CANGRELOR,3.0,Recruiting,EFO_0000556,ischemia,,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL4297589,SELATOGREL,3.0,Enrolling by invitation,EFO_0008583,acute myocardial infarction,,CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL2103828,ELINOGREL,2.0,Terminated,EFO_0000612,myocardial infarction,,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL1162175,REGRELOR,2.0,Terminated,EFO_0001645,coronary artery disease,,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21
G alpha (i) signalling events,R-HSA-418594,https://reactome.org/PathwayBrowser/#/R-HSA-418594,P2RY12,ENSG00000169313,CHEMBL261244,REGRELOR DISODIUM,2.0,Terminated,EFO_0001645,coronary artery disease,,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+]
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2A,ENSG00000150594,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA2B,ENSG00000274286,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL27810,CELIPROLOL,4.0,,EFO_0000319,cardiovascular disease,,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL862,GUANFACINE,4.0,,EFO_0000537,hypertension,,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200494,GUANFACINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL134,CLONIDINE,4.0,,EFO_0000537,hypertension,,Clc1cccc(Cl)c1NC1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1705,CLONIDINE HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,Cl.Clc1cccc(Cl)c1NC1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2062257,BRIMONIDINE TARTRATE,4.0,,EFO_0000537,hypertension,,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL459,METHYLDOPA,4.0,,EFO_0000537,hypertension,,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL844,BRIMONIDINE,4.0,,EFO_0005751,eye allergy,,Brc1c(NC2=NCCN2)ccc2nccnc12
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL17860,LOFEXIDINE,4.0,,EFO_0003890,drug dependence,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL654,MIRTAZAPINE,4.0,,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3C2C1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,4.0,,EFO_0005800,substance withdrawal syndrome,,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,4.0,,HP_0001257,Spasticity,,Cl.Clc1ccc2nsnc2c1NC1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL647,APRACLONIDINE,4.0,,MONDO_0005041,glaucoma,,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL778,DEXMEDETOMIDINE,3.0,Recruiting,EFO_0000546,injury,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL10316,IDAZOXAN,3.0,Withdrawn,MONDO_0002009,major depressive disorder,,c1ccc2c(c1)OCC(C1=NCCN1)O2
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1079,TIZANIDINE,3.0,Completed,HP_0003419,Low back pain,,Clc1ccc2nsnc2c1NC1=NCCN1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL1255582,FIPAMEZOLE,2.0,Completed,MONDO_0005180,Parkinson disease,,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,ADRA2A,ENSG00000150594,CHEMBL420,GUANABENZ,1.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,N=C(N)N/N=C/c1c(Cl)cccc1Cl
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148,https://reactome.org/PathwayBrowser/#/R-HSA-1445148,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,R-HSA-190840,https://reactome.org/PathwayBrowser/#/R-HSA-190840,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Gap junction assembly,R-HSA-190861,https://reactome.org/PathwayBrowser/#/R-HSA-190861,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
MHC class II antigen presentation,R-HSA-2132295,https://reactome.org/PathwayBrowser/#/R-HSA-2132295,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Separation of Sister Chromatids,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Resolution of Sister Chromatid Cohesion,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Regulation of PLK1 Activity at G2/M Transition,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1082407,ENZALUTAMIDE,4.0,Unknown status,EFO_0000196,metastatic prostate cancer,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL806,FLUTAMIDE,4.0,,EFO_0000313,carcinoma,,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL409,BICALUTAMIDE,4.0,,EFO_0000313,carcinoma,,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL2107067,TESTOSTERONE UNDECANOATE,4.0,,EFO_0000616,neoplasm,,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1200335,TESTOSTERONE ENANTHATE,4.0,,EFO_0000616,neoplasm,,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1201101,TESTOSTERONE CYPIONATE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1274,NILUTAMIDE,4.0,,EFO_0000616,neoplasm,,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1445,FLUOXYMESTERONE,4.0,,EFO_0000616,neoplasm,,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL386630,TESTOSTERONE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL4297185,DAROLUTAMIDE,4.0,,EFO_0000616,neoplasm,,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL254328,ABIRATERONE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3183409,APALUTAMIDE,4.0,"Active, not recruiting",EFO_0000673,prostate adenocarcinoma,,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1479,DANAZOL,4.0,,EFO_0001065,endometriosis,,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3590187,CLASCOTERONE,4.0,"Active, not recruiting",EFO_0003894,acne,,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1395,METHYLTESTOSTERONE,4.0,,MONDO_0002146,hypogonadism,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1200436,OXANDROLONE,3.0,Withdrawn,EFO_0000546,injury,,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL4594417,PRUXELUTAMIDE,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1738889,ENOBOSARM,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL4650276,SHR3680,3.0,"Active, not recruiting",MONDO_0008315,prostate cancer,,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL2105738,GALETERONE,3.0,Terminated,MONDO_0008315,prostate cancer,,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL2079587,STANOZOLOL,2.0,Not yet recruiting,EFO_0000198,myelodysplastic syndrome,,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3545092,CR 1447,2.0,Terminated,EFO_0000304,breast adenocarcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3542265,LY2452473,2.0,Terminated,EFO_0000284,benign prostatic hyperplasia,,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3264610,SEVITERONEL,2.0,Terminated,EFO_0000616,neoplasm,,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1200946,NANDROLONE DECANOATE,2.0,Completed,EFO_0003964,hip fracture,,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL5170587,VK5211,2.0,Completed,EFO_0003964,hip fracture,,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL128748,DIMETHYLCURCUMIN,2.0,Completed,EFO_0003894,acne,,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3545333,MK-0773,2.0,Completed,EFO_1000653,sarcopenia,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3545174,GSK2881078,2.0,Completed,HP_0004326,Cachexia,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3545046,GSK2849466,1.0,Completed,HP_0004326,Cachexia,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL1170,TESTOSTERONE PROPIONATE,1.0,Suspended,EFO_1001271,Atrophic Vaginitis,,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL3545237,HE3235,1.0,Completed,MONDO_0008315,prostate cancer,,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL37676,APC-100,1.0,Unknown status,MONDO_0008315,prostate cancer,,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,AR,ENSG00000169083,CHEMBL2346976,AZD3514,1.0,Completed,MONDO_0008315,prostate cancer,,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,R-HSA-3371497,https://reactome.org/PathwayBrowser/#/R-HSA-3371497,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Loss of Nlp from mitotic centrosomes,R-HSA-380259,https://reactome.org/PathwayBrowser/#/R-HSA-380259,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Recruitment of mitotic centrosome proteins and complexes,R-HSA-380270,https://reactome.org/PathwayBrowser/#/R-HSA-380270,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Loss of proteins required for interphase microtubule organization from the centrosome,R-HSA-380284,https://reactome.org/PathwayBrowser/#/R-HSA-380284,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Recruitment of NuMA to mitotic centrosomes,R-HSA-380320,https://reactome.org/PathwayBrowser/#/R-HSA-380320,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Prefoldin mediated transfer of substrate to CCT/TriC,R-HSA-389957,https://reactome.org/PathwayBrowser/#/R-HSA-389957,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Formation of tubulin folding intermediates by CCT/TriC,R-HSA-389960,https://reactome.org/PathwayBrowser/#/R-HSA-389960,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Post-chaperonin tubulin folding pathway,R-HSA-389977,https://reactome.org/PathwayBrowser/#/R-HSA-389977,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Recycling pathway of L1,R-HSA-437239,https://reactome.org/PathwayBrowser/#/R-HSA-437239,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Cilium Assembly,R-HSA-5617833,https://reactome.org/PathwayBrowser/#/R-HSA-5617833,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Anchoring of the basal body to the plasma membrane,R-HSA-5620912,https://reactome.org/PathwayBrowser/#/R-HSA-5620912,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Intraflagellar transport,R-HSA-5620924,https://reactome.org/PathwayBrowser/#/R-HSA-5620924,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
RHO GTPases activate IQGAPs,R-HSA-5626467,https://reactome.org/PathwayBrowser/#/R-HSA-5626467,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
RHO GTPases Activate Formins,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,MMP8,ENSG00000118113,CHEMBL1200699,DOXYCYCLINE,4.0,,DOID_7551,gonorrhea,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,MMP8,ENSG00000118113,CHEMBL3989740,DOXYCYCLINE HYCLATE,4.0,Completed,EFO_0003894,acne,,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,MMP8,ENSG00000118113,CHEMBL1433,DOXYCYCLINE ANHYDROUS,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,MMP8,ENSG00000118113,CHEMBL76222,REBIMASTAT,2.0,Completed,EFO_0000673,prostate adenocarcinoma,,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,MMP8,ENSG00000118113,CHEMBL440498,CTS-1027,2.0,Terminated,EFO_0003047,hepatitis C virus infection,,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,MMP8,ENSG00000118113,CHEMBL2364574,DOXYCYCLINE CALCIUM,0.5,Terminated,EFO_0003102,osteomyelitis,,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
COPI-mediated anterograde transport,R-HSA-6807878,https://reactome.org/PathwayBrowser/#/R-HSA-6807878,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
COPI-dependent Golgi-to-ER retrograde traffic,R-HSA-6811434,https://reactome.org/PathwayBrowser/#/R-HSA-6811434,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
COPI-independent Golgi-to-ER retrograde traffic,R-HSA-6811436,https://reactome.org/PathwayBrowser/#/R-HSA-6811436,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Mitotic Prometaphase,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
AURKA Activation by TPX2,R-HSA-8854518,https://reactome.org/PathwayBrowser/#/R-HSA-8854518,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Carboxyterminal post-translational modifications of tubulin,R-HSA-8955332,https://reactome.org/PathwayBrowser/#/R-HSA-8955332,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
HCMV Early Events,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Assembly and cell surface presentation of NMDA receptors,R-HSA-9609736,https://reactome.org/PathwayBrowser/#/R-HSA-9609736,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Activation of AMPK downstream of NMDARs,R-HSA-9619483,https://reactome.org/PathwayBrowser/#/R-HSA-9619483,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Aggrephagy,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
EML4 and NUDC in mitotic spindle formation,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Sealing of the nuclear envelope (NE) by ESCRT-III,R-HSA-9668328,https://reactome.org/PathwayBrowser/#/R-HSA-9668328,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
Kinesins,R-HSA-983189,https://reactome.org/PathwayBrowser/#/R-HSA-983189,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1742994,BRENTUXIMAB VEDOTIN,4.0,,EFO_0000183,Hodgkins lymphoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL378544,VINBLASTINE SULFATE,4.0,,EFO_0000183,Hodgkins lymphoma,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3545252,DOCETAXEL,4.0,,EFO_0000228,adenocarcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1201752,IXABEPILONE,4.0,,EFO_0000305,breast carcinoma,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1743082,TRASTUZUMAB EMTANSINE,4.0,,EFO_0000305,breast carcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL428647,PACLITAXEL,4.0,,EFO_0000305,breast carcinoma,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1683544,ERIBULIN MESYLATE,4.0,,EFO_0000305,breast carcinoma,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3301582,POLATUZUMAB VEDOTIN,4.0,,EFO_0000403,diffuse large B-cell lymphoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1201748,CABAZITAXEL,4.0,,EFO_0000616,neoplasm,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL90555,VINCRISTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1683590,ERIBULIN,4.0,,EFO_0000616,neoplasm,,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL159,VINBLASTINE,4.0,,EFO_0000616,neoplasm,,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3301589,ENFORTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL553025,VINORELBINE,4.0,,EFO_0000616,neoplasm,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297841,TISOTUMAB VEDOTIN,4.0,,EFO_0000616,neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4298209,BELANTAMAB MAFODOTIN,4.0,,EFO_0000616,neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL107,COLCHICINE,4.0,,EFO_0004274,gout,,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,4.0,,EFO_1001100,peritoneal neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL92,DOCETAXEL ANHYDROUS,3.0,Not yet recruiting,EFO_0000181,head and neck squamous cell carcinoma,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL501867,VINCRISTINE SULFATE,3.0,Completed,EFO_0000096,neoplasm of mature B-cells,,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL538943,VINORELBINE TARTRATE,3.0,Completed,EFO_0000183,Hodgkins lymphoma,,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4279455,LAROTAXEL,3.0,Completed,EFO_0000294,bladder tumor,,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2110725,VINFLUNINE,3.0,Completed,EFO_0000294,bladder tumor,,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2108628,PACLITAXEL POLIGLUMEX,3.0,,EFO_0000616,neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL572284,OMBRABULIN,3.0,Completed,EFO_0000691,sarcoma,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1096380,PLINABULIN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3990032,TELISOTUZUMAB VEDOTIN,3.0,Withdrawn,EFO_0003060,non-small cell lung carcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4298098,TUSAMITAMAB RAVTANSINE,3.0,"Active, not recruiting",EFO_0003060,non-small cell lung carcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1206232,FOSBRETABULIN,3.0,Withdrawn,MONDO_0002108,thyroid cancer,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL94657,PATUPILONE,3.0,Completed,EFO_1001100,peritoneal neoplasm,,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297440,T-900607,2.0,Unknown status,EFO_0000182,hepatocellular carcinoma,,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4298045,INDUSATUMAB VEDOTIN,2.0,Terminated,EFO_0000503,gastric adenocarcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1089636,ANG1005,2.0,Completed,EFO_0000519,glioblastoma multiforme,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2304041,SAGOPILONE,2.0,Completed,EFO_0000519,glioblastoma multiforme,,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL492399,VERUBULIN,2.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL39541,DOLASTATIN-10,2.0,Completed,EFO_0000574,lymphoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1743037,LORVOTUZUMAB MERTANSINE,2.0,Completed,EFO_0000565,leukemia,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL289351,FOSBRETABULIN DISODIUM,2.0,Completed,EFO_0000616,neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2107759,MILATAXEL,2.0,Unknown status,EFO_0000588,mesothelioma,,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL20684,ABT-751,2.0,Completed,EFO_0000621,neuroblastoma,,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297892,ANVATABART OPADOTIN,2.0,Withdrawn,EFO_0000616,neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4594455,AGS-16C3F,2.0,Completed,EFO_0000681,renal cell carcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,2.0,Completed,EFO_0000637,osteosarcoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3989512,SOBLIDOTIN,2.0,Completed,EFO_0000691,sarcoma,,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL552212,LEXIBULIN,2.0,Terminated,EFO_0001378,multiple myeloma,,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297296,KOS-1584,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4298101,LADIRATUZUMAB VEDOTIN,2.0,Recruiting,EFO_0003869,breast neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297268,BMS-275183,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,2.0,Completed,EFO_1001901,neuroendocrine neoplasm,,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2103826,DAVUNETIDE,2.0,Completed,HP_0100543,Cognitive impairment,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297636,PLOCABULIN,2.0,Completed,MONDO_0005575,colorectal cancer,,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297938,LIFASTUZUMAB VEDOTIN,2.0,Terminated,MONDO_0008170,ovarian cancer,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL96172,EPOTHILONE D,2.0,Terminated,MONDO_0008903,lung cancer,,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297736,PRALUZATAMAB RAVTANSINE,2.0,Completed,MONDO_0007254,breast cancer,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3301585,PINATUZUMAB VEDOTIN,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL49642,INDIBULIN,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297935,RG-7841,1.0,Completed,EFO_0000616,neoplasm,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,1.0,Terminated,EFO_0001378,multiple myeloma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2109574,ASG-5ME,1.0,Completed,EFO_0001663,prostate carcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3545372,SOFITUZUMAB VEDOTIN,1.0,Completed,EFO_0002618,pancreatic carcinoma,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL4650293,APRUTUMAB IXADOTIN,1.0,Terminated,MONDO_0004992,cancer,,
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL2103852,CROLIBULIN,1.0,Completed,MONDO_0002108,thyroid cancer,,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC
PKR-mediated signaling,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TUBB4B,ENSG00000188229,CHEMBL3833306,VANDORTUZUMAB VEDOTIN,1.0,Completed,MONDO_0008315,prostate cancer,,
Activation of NF-kappaB in B cells,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
Activation of NF-kappaB in B cells,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
Activation of NF-kappaB in B cells,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL1873475,IBRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3707348,ACALABRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4594293,ACALABRUTINIB MALEATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3936761,ZANUBRUTINIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL5314649,RITLECITINIB TOSYLATE,4.0,,EFO_0004192,alopecia areata,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4650485,PIRTOBRUTINIB,4.0,,EFO_1001469,Mantle cell lymphoma,,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4650321,ORELABRUTINIB,3.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4065122,FENEBRUTINIB,3.0,"Active, not recruiting",EFO_0003840,chronic progressive multiple sclerosis,,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4297865,ABIVERTINIB,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4085457,RITLECITINIB,3.0,Recruiting,EFO_0004208,Vitiligo,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4297866,ABIVERTINIB MALEATE,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4650323,TOLEBRUTINIB,3.0,Recruiting,EFO_0008520,primary progressive multiple sclerosis,,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3702854,RILZABRUTINIB,3.0,Recruiting,EFO_0007160,autoimmune thrombocytopenic purpura,,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4072833,EVOBRUTINIB,3.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4650338,EDRALBRUTINIB,2.0,Recruiting,EFO_0000096,neoplasm of mature B-cells,,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4071161,TIRABRUTINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3301600,SPEBRUTINIB BESYLATE,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3301625,SPEBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4163691,POSELTINIB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3900554,BMS-986142,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4594348,ELSUBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL4297674,BRANEBRUTINIB,1.0,Completed,EFO_0000685,rheumatoid arthritis,,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,BTK,ENSG00000010671,CHEMBL3545193,MSC-2364447,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
ER-Phagosome pathway,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
NOD1/2 Signaling Pathway,R-HSA-168638,https://reactome.org/PathwayBrowser/#/R-HSA-168638,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
NOD1/2 Signaling Pathway,R-HSA-168638,https://reactome.org/PathwayBrowser/#/R-HSA-168638,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
NOD1/2 Signaling Pathway,R-HSA-168638,https://reactome.org/PathwayBrowser/#/R-HSA-168638,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
"TICAM1, RIP1-mediated IKK complex recruitment",R-HSA-168927,https://reactome.org/PathwayBrowser/#/R-HSA-168927,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
"TICAM1, RIP1-mediated IKK complex recruitment",R-HSA-168927,https://reactome.org/PathwayBrowser/#/R-HSA-168927,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
"TICAM1, RIP1-mediated IKK complex recruitment",R-HSA-168927,https://reactome.org/PathwayBrowser/#/R-HSA-168927,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
RIP-mediated NFkB activation via ZBP1,R-HSA-1810476,https://reactome.org/PathwayBrowser/#/R-HSA-1810476,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
RIP-mediated NFkB activation via ZBP1,R-HSA-1810476,https://reactome.org/PathwayBrowser/#/R-HSA-1810476,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
RIP-mediated NFkB activation via ZBP1,R-HSA-1810476,https://reactome.org/PathwayBrowser/#/R-HSA-1810476,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
p75NTR recruits signalling complexes,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
p75NTR recruits signalling complexes,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
p75NTR recruits signalling complexes,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
NF-kB is activated and signals survival,R-HSA-209560,https://reactome.org/PathwayBrowser/#/R-HSA-209560,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
NF-kB is activated and signals survival,R-HSA-209560,https://reactome.org/PathwayBrowser/#/R-HSA-209560,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
NF-kB is activated and signals survival,R-HSA-209560,https://reactome.org/PathwayBrowser/#/R-HSA-209560,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
TAK1-dependent IKK and NF-kappa-B activation,R-HSA-445989,https://reactome.org/PathwayBrowser/#/R-HSA-445989,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
TAK1-dependent IKK and NF-kappa-B activation,R-HSA-445989,https://reactome.org/PathwayBrowser/#/R-HSA-445989,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
TAK1-dependent IKK and NF-kappa-B activation,R-HSA-445989,https://reactome.org/PathwayBrowser/#/R-HSA-445989,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1201580,ADALIMUMAB,4.0,Completed,EFO_0000384,Crohn's disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1201581,INFLIXIMAB,4.0,,EFO_0000384,Crohn's disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1201831,CERTOLIZUMAB PEGOL,4.0,,EFO_0000384,Crohn's disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1201572,ETANERCEPT,4.0,,EFO_0000540,immune system disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1201833,GOLIMUMAB,4.0,,EFO_0000540,immune system disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL2107911,ONERCEPT,3.0,Terminated,EFO_0003778,psoriatic arthritis,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL2108887,AFELIMOMAB,2.0,,EFO_0000540,immune system disease,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1743057,PEGSUNERCEPT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL1743054,OZORALIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL2108739,PLACULUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Regulation of TNFR1 signaling,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,TNF,ENSG00000232810,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1201580,ADALIMUMAB,4.0,Completed,EFO_0000384,Crohn's disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1201581,INFLIXIMAB,4.0,,EFO_0000384,Crohn's disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1201831,CERTOLIZUMAB PEGOL,4.0,,EFO_0000384,Crohn's disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1201572,ETANERCEPT,4.0,,EFO_0000540,immune system disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1201833,GOLIMUMAB,4.0,,EFO_0000540,immune system disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL2107911,ONERCEPT,3.0,Terminated,EFO_0003778,psoriatic arthritis,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL2108887,AFELIMOMAB,2.0,,EFO_0000540,immune system disease,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1743057,PEGSUNERCEPT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL1743054,OZORALIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL2108739,PLACULUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,TNF,ENSG00000232810,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
IKBKB deficiency causes SCID,R-HSA-5602636,https://reactome.org/PathwayBrowser/#/R-HSA-5602636,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
IKBKB deficiency causes SCID,R-HSA-5602636,https://reactome.org/PathwayBrowser/#/R-HSA-5602636,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
IKBKB deficiency causes SCID,R-HSA-5602636,https://reactome.org/PathwayBrowser/#/R-HSA-5602636,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),R-HSA-5603027,https://reactome.org/PathwayBrowser/#/R-HSA-5603027,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),R-HSA-5603027,https://reactome.org/PathwayBrowser/#/R-HSA-5603027,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),R-HSA-5603027,https://reactome.org/PathwayBrowser/#/R-HSA-5603027,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
IkBA variant leads to EDA-ID,R-HSA-5603029,https://reactome.org/PathwayBrowser/#/R-HSA-5603029,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
IkBA variant leads to EDA-ID,R-HSA-5603029,https://reactome.org/PathwayBrowser/#/R-HSA-5603029,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
IkBA variant leads to EDA-ID,R-HSA-5603029,https://reactome.org/PathwayBrowser/#/R-HSA-5603029,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
MAP3K8 (TPL2)-dependent MAPK1/3 activation,R-HSA-112409,https://reactome.org/PathwayBrowser/#/R-HSA-112409,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
MAP3K8 (TPL2)-dependent MAPK1/3 activation,R-HSA-112409,https://reactome.org/PathwayBrowser/#/R-HSA-112409,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
MAP3K8 (TPL2)-dependent MAPK1/3 activation,R-HSA-112409,https://reactome.org/PathwayBrowser/#/R-HSA-112409,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1R1,ENSG00000115594,CHEMBL1201570,ANAKINRA,4.0,,EFO_0000540,immune system disease,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1R1,ENSG00000115594,CHEMBL2109458,AMG-108,2.0,Withdrawn,EFO_0000400,diabetes mellitus,,
Interleukin-1 signaling,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,IL1R1,ENSG00000115594,CHEMBL2109607,MEDI-8968,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
TRAF6 mediated NF-kB activation,R-HSA-933542,https://reactome.org/PathwayBrowser/#/R-HSA-933542,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
TRAF6 mediated NF-kB activation,R-HSA-933542,https://reactome.org/PathwayBrowser/#/R-HSA-933542,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
TRAF6 mediated NF-kB activation,R-HSA-933542,https://reactome.org/PathwayBrowser/#/R-HSA-933542,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
IRAK1 recruits IKK complex,R-HSA-937039,https://reactome.org/PathwayBrowser/#/R-HSA-937039,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
IRAK1 recruits IKK complex,R-HSA-937039,https://reactome.org/PathwayBrowser/#/R-HSA-937039,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
IRAK1 recruits IKK complex,R-HSA-937039,https://reactome.org/PathwayBrowser/#/R-HSA-937039,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
IKK complex recruitment mediated by RIP1,R-HSA-937041,https://reactome.org/PathwayBrowser/#/R-HSA-937041,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
IKK complex recruitment mediated by RIP1,R-HSA-937041,https://reactome.org/PathwayBrowser/#/R-HSA-937041,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
IKK complex recruitment mediated by RIP1,R-HSA-937041,https://reactome.org/PathwayBrowser/#/R-HSA-937041,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL2364653,ANIFROLUMAB,4.0,,EFO_0000540,immune system disease,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL1201558,INTERFERON ALFA-2B,4.0,,EFO_0000558,Kaposi's sarcoma,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL1201557,INTERFERON ALFACON-1,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL1201561,PEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL1201562,INTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL1201560,PEGINTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL1201563,INTERFERON BETA-1B,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL2108508,INTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL2108677,PEGINTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL4297819,ROPEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL2107842,ALBINTERFERON ALFA-2B,3.0,,EFO_0000616,neoplasm,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IFNAR1,ENSG00000142166,CHEMBL2109047,INTERFERON ALFA-N3,2.0,Completed,EFO_0000694,severe acute respiratory syndrome,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL1743034,IXEKIZUMAB,4.0,,EFO_0000540,immune system disease,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL1743068,SECUKINUMAB,4.0,,EFO_0000540,immune system disease,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL4297700,BIMEKIZUMAB,4.0,,EFO_0000540,immune system disease,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL4298102,VUNAKIZUMAB,3.0,Not yet recruiting,EFO_0000676,psoriasis,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL4298023,M-1095,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL4297686,IZOKIBEP,3.0,"Active, not recruiting",EFO_1000710,hidradenitis suppurativa,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL3990000,TIBULIZUMAB,2.0,Withdrawn,EFO_0000699,Sjogren syndrome,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL4297926,CJM-112,2.0,Completed,EFO_0003894,acne,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,IL17A,ENSG00000112115,CHEMBL2109470,PERAKIZUMAB,1.0,Completed,EFO_0003778,psoriatic arthritis,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation,R-HSA-975144,https://reactome.org/PathwayBrowser/#/R-HSA-975144,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation,R-HSA-975144,https://reactome.org/PathwayBrowser/#/R-HSA-975144,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation,R-HSA-975144,https://reactome.org/PathwayBrowser/#/R-HSA-975144,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
SLC15A4:TASL-dependent IRF5 activation,R-HSA-9860276,https://reactome.org/PathwayBrowser/#/R-HSA-9860276,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
SLC15A4:TASL-dependent IRF5 activation,R-HSA-9860276,https://reactome.org/PathwayBrowser/#/R-HSA-9860276,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
SLC15A4:TASL-dependent IRF5 activation,R-HSA-9860276,https://reactome.org/PathwayBrowser/#/R-HSA-9860276,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL484785,CRISABOROLE,4.0,"Active, not recruiting",EFO_0000274,atopic eczema,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL193240,ROFLUMILAST,4.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL514800,APREMILAST,4.0,,EFO_0000540,immune system disease,,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,4.0,,EFO_0003901,dysuria,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL190,THEOPHYLLINE,4.0,,EFO_0006505,chronic bronchitis,,Cn1c(=O)c2[nH]cnc2n(C)c1=O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL1096,AMLEXANOX,4.0,,HP_0006536,Airway obstruction,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL1370561,AMINOPHYLLINE,4.0,,MONDO_0004979,asthma,,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL1200434,OXTRIPHYLLINE,4.0,,HP_0006536,Airway obstruction,,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL1752,DYPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL3989968,DIFAMILAST,3.0,Completed,EFO_0000274,atopic eczema,,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL511115,CILOMILAST,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL3113974,TRANIMILAST,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL4594287,ENSIFENTRINE,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL332750,TETOMILAST,3.0,Completed,EFO_0000729,ulcerative colitis,,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL551978,DROTAVERINE,3.0,,EFO_0010282,gastrointestinal disease,,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL4541964,ZATOLMILAST,3.0,Enrolling by invitation,MONDO_0010383,fragile X syndrome,,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL217899,TOFIMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL4297520,OGLEMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL570015,GSK-256066,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL3989967,LOTAMILAST,2.0,Completed,EFO_0000274,atopic eczema,,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL485629,MK-0873,2.0,Terminated,EFO_0000341,chronic obstructive pulmonary disease,,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL4297527,REVAMILAST,2.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL4297287,HT-0712,2.0,Completed,EFO_0001072,memory impairment,,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL4297460,DOVRAMILAST,2.0,Completed,EFO_0003834,cutaneous lupus erythematosus,,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL1493,FLAVOXATE,2.0,,HP_0000103,Polyuria,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,PDE4D,ENSG00000113448,CHEMBL63,ROLIPRAM,2.0,Completed,MONDO_0005301,multiple sclerosis,,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1
Modulation of host responses by IFN-stimulated genes,R-HSA-9909505,https://reactome.org/PathwayBrowser/#/R-HSA-9909505,IKBKB,ENSG00000104365,CHEMBL1762621,BARDOXOLONE METHYL,3.0,Terminated,EFO_0000401,diabetic nephropathy,,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
Modulation of host responses by IFN-stimulated genes,R-HSA-9909505,https://reactome.org/PathwayBrowser/#/R-HSA-9909505,IKBKB,ENSG00000104365,CHEMBL3545168,IMD-1041,2.0,Unknown status,EFO_0000341,chronic obstructive pulmonary disease,,
Modulation of host responses by IFN-stimulated genes,R-HSA-9909505,https://reactome.org/PathwayBrowser/#/R-HSA-9909505,IKBKB,ENSG00000104365,CHEMBL3544945,SAR-113945,2.0,Completed,EFO_0004616,"osteoarthritis, knee",,
Interleukin-1 processing,R-HSA-448706,https://reactome.org/PathwayBrowser/#/R-HSA-448706,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
Interleukin-1 processing,R-HSA-448706,https://reactome.org/PathwayBrowser/#/R-HSA-448706,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-1 processing,R-HSA-448706,https://reactome.org/PathwayBrowser/#/R-HSA-448706,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
Interleukin-1 processing,R-HSA-448706,https://reactome.org/PathwayBrowser/#/R-HSA-448706,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
CLEC7A/inflammasome pathway,R-HSA-5660668,https://reactome.org/PathwayBrowser/#/R-HSA-5660668,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
CLEC7A/inflammasome pathway,R-HSA-5660668,https://reactome.org/PathwayBrowser/#/R-HSA-5660668,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
CLEC7A/inflammasome pathway,R-HSA-5660668,https://reactome.org/PathwayBrowser/#/R-HSA-5660668,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
CLEC7A/inflammasome pathway,R-HSA-5660668,https://reactome.org/PathwayBrowser/#/R-HSA-5660668,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL3545221,AZD2423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL3707228,PLOZALIZUMAB,2.0,Withdrawn,EFO_0000319,cardiovascular disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL2178573,ILACIRNON,2.0,Completed,EFO_0000401,diabetic nephropathy,,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL4297538,MK-0812,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL4650501,PF-4136309,2.0,Terminated,EFO_0004220,chronic hepatitis C virus infection,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL4457723,BMS-741672,2.0,Completed,EFO_0005762,neuropathic pain,,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR2,ENSG00000121807,CHEMBL2204263,JNJ-41443532,2.0,Completed,MONDO_0005148,type 2 diabetes mellitus,,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL1201187,MARAVIROC,4.0,Completed,EFO_0000180,HIV-1 infection,,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL1255794,APLAVIROC,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL1668019,APLAVIROC HYDROCHLORIDE,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL82301,VICRIVIROC,3.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL2109343,LERONLIMAB,3.0,Suspended,MONDO_0100096,COVID-19,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL1951914,AZD5672,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL1649931,PF-232798,2.0,Completed,EFO_0000764,HIV infection,,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL2107384,VICRIVIROC MALEATE,2.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL1688243,INCB-9471,2.0,Completed,EFO_0000764,HIV infection,,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL2109342,HGS-1025,1.0,Withdrawn,EFO_0000729,ulcerative colitis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CCR5,ENSG00000160791,CHEMBL2109341,CCR5MAB004,1.0,Completed,EFO_0000764,HIV infection,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CSF2,ENSG00000164400,CHEMBL3039547,PEXASTIMOGENE DEVACIREPVEC,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CSF2,ENSG00000164400,CHEMBL2109433,OTILIMAB,3.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CSF2,ENSG00000164400,CHEMBL3707325,LENZILUMAB,3.0,"Active, not recruiting",EFO_0003106,pneumonia,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CSF2,ENSG00000164400,CHEMBL1743044,NAMILUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CSF2,ENSG00000164400,CHEMBL4650518,PLONMARLIMAB,2.0,Completed,MONDO_0100096,COVID-19,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,CSF2,ENSG00000164400,CHEMBL2109430,GIMSILUMAB,2.0,Completed,MONDO_0100096,COVID-19,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL10RB,ENSG00000243646,CHEMBL3989992,PEGILODECAKIN,3.0,Completed,EFO_0002618,pancreatic carcinoma,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL10RB,ENSG00000243646,CHEMBL2108723,PEGINTERFERON LAMBDA-1A,3.0,Completed,EFO_0003047,hepatitis C virus infection,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL10RB,ENSG00000243646,CHEMBL4594542,EFLEPEDOCOKIN ALFA,2.0,Terminated,MONDO_0100096,COVID-19,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1R1,ENSG00000115594,CHEMBL1201570,ANAKINRA,4.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1R1,ENSG00000115594,CHEMBL2109458,AMG-108,2.0,Withdrawn,EFO_0000400,diabetes mellitus,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL1R1,ENSG00000115594,CHEMBL2109607,MEDI-8968,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1201580,ADALIMUMAB,4.0,Completed,EFO_0000384,Crohn's disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1201581,INFLIXIMAB,4.0,,EFO_0000384,Crohn's disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1201831,CERTOLIZUMAB PEGOL,4.0,,EFO_0000384,Crohn's disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1201572,ETANERCEPT,4.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1201833,GOLIMUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL2107911,ONERCEPT,3.0,Terminated,EFO_0003778,psoriatic arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL2108887,AFELIMOMAB,2.0,,EFO_0000540,immune system disease,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1743057,PEGSUNERCEPT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL1743054,OZORALIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL2108739,PLACULUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TNF,ENSG00000232810,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-10 signaling,R-HSA-6783783,https://reactome.org/PathwayBrowser/#/R-HSA-6783783,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Purinergic signaling in leishmaniasis infection,R-HSA-9660826,https://reactome.org/PathwayBrowser/#/R-HSA-9660826,IL1B,ENSG00000125538,CHEMBL1201830,RILONACEPT,4.0,,EFO_0000540,immune system disease,,
Purinergic signaling in leishmaniasis infection,R-HSA-9660826,https://reactome.org/PathwayBrowser/#/R-HSA-9660826,IL1B,ENSG00000125538,CHEMBL1201834,CANAKINUMAB,4.0,,EFO_0000540,immune system disease,,
Purinergic signaling in leishmaniasis infection,R-HSA-9660826,https://reactome.org/PathwayBrowser/#/R-HSA-9660826,IL1B,ENSG00000125538,CHEMBL1743026,GEVOKIZUMAB,3.0,Terminated,EFO_0003780,Behcet's syndrome,,
Purinergic signaling in leishmaniasis infection,R-HSA-9660826,https://reactome.org/PathwayBrowser/#/R-HSA-9660826,IL1B,ENSG00000125538,CHEMBL4594518,LUTIKIZUMAB,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6R,ENSG00000160712,CHEMBL2108730,SARILUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6R,ENSG00000160712,CHEMBL3833307,SATRALIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6R,ENSG00000160712,CHEMBL1237022,TOCILIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6R,ENSG00000160712,CHEMBL4650406,LEVILIMAB,3.0,"Active, not recruiting",EFO_0000685,rheumatoid arthritis,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,IL6R,ENSG00000160712,CHEMBL3833343,VOBARILIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6R,ENSG00000160712,CHEMBL2108730,SARILUMAB,4.0,,EFO_0000540,immune system disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6R,ENSG00000160712,CHEMBL3833307,SATRALIZUMAB,4.0,,EFO_0000540,immune system disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6R,ENSG00000160712,CHEMBL1237022,TOCILIZUMAB,4.0,,EFO_0000540,immune system disease,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6R,ENSG00000160712,CHEMBL4650406,LEVILIMAB,3.0,"Active, not recruiting",EFO_0000685,rheumatoid arthritis,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,IL6R,ENSG00000160712,CHEMBL3833343,VOBARILIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6R,ENSG00000160712,CHEMBL2108730,SARILUMAB,4.0,,EFO_0000540,immune system disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6R,ENSG00000160712,CHEMBL3833307,SATRALIZUMAB,4.0,,EFO_0000540,immune system disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6R,ENSG00000160712,CHEMBL1237022,TOCILIZUMAB,4.0,,EFO_0000540,immune system disease,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6R,ENSG00000160712,CHEMBL4650406,LEVILIMAB,3.0,"Active, not recruiting",EFO_0000685,rheumatoid arthritis,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,IL6R,ENSG00000160712,CHEMBL3833343,VOBARILIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,IL10RB,ENSG00000243646,CHEMBL3989992,PEGILODECAKIN,3.0,Completed,EFO_0002618,pancreatic carcinoma,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,IL10RB,ENSG00000243646,CHEMBL2108723,PEGINTERFERON LAMBDA-1A,3.0,Completed,EFO_0003047,hepatitis C virus infection,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,IL10RB,ENSG00000243646,CHEMBL4594542,EFLEPEDOCOKIN ALFA,2.0,Terminated,MONDO_0100096,COVID-19,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,IL10RB,ENSG00000243646,CHEMBL3989992,PEGILODECAKIN,3.0,Completed,EFO_0002618,pancreatic carcinoma,,
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,IL10RB,ENSG00000243646,CHEMBL2108723,PEGINTERFERON LAMBDA-1A,3.0,Completed,EFO_0003047,hepatitis C virus infection,,
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,IL10RB,ENSG00000243646,CHEMBL4594542,EFLEPEDOCOKIN ALFA,2.0,Terminated,MONDO_0100096,COVID-19,,
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL2364653,ANIFROLUMAB,4.0,,EFO_0000540,immune system disease,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL1201558,INTERFERON ALFA-2B,4.0,,EFO_0000558,Kaposi's sarcoma,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL1201557,INTERFERON ALFACON-1,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL1201561,PEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL1201562,INTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL1201560,PEGINTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL1201563,INTERFERON BETA-1B,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL2108508,INTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL2108677,PEGINTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL4297819,ROPEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL2107842,ALBINTERFERON ALFA-2B,3.0,,EFO_0000616,neoplasm,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,IFNAR1,ENSG00000142166,CHEMBL2109047,INTERFERON ALFA-N3,2.0,Completed,EFO_0000694,severe acute respiratory syndrome,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Interferon alpha/beta signaling,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL2364653,ANIFROLUMAB,4.0,,EFO_0000540,immune system disease,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL1201558,INTERFERON ALFA-2B,4.0,,EFO_0000558,Kaposi's sarcoma,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL1201557,INTERFERON ALFACON-1,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL1201561,PEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL1201562,INTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL1201560,PEGINTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL1201563,INTERFERON BETA-1B,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL2108508,INTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL2108677,PEGINTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL4297819,ROPEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL2107842,ALBINTERFERON ALFA-2B,3.0,,EFO_0000616,neoplasm,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,IFNAR1,ENSG00000142166,CHEMBL2109047,INTERFERON ALFA-N3,2.0,Completed,EFO_0000694,severe acute respiratory syndrome,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Regulation of IFNA/IFNB signaling,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL2364653,ANIFROLUMAB,4.0,,EFO_0000540,immune system disease,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL1201558,INTERFERON ALFA-2B,4.0,,EFO_0000558,Kaposi's sarcoma,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL1201557,INTERFERON ALFACON-1,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL1201561,PEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL1201562,INTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL1201560,PEGINTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL1201563,INTERFERON BETA-1B,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL2108508,INTERFERON ALFA-2A,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL2108677,PEGINTERFERON BETA-1A,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL4297819,ROPEGINTERFERON ALFA-2B,4.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL2107842,ALBINTERFERON ALFA-2B,3.0,,EFO_0000616,neoplasm,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,IFNAR1,ENSG00000142166,CHEMBL2109047,INTERFERON ALFA-N3,2.0,Completed,EFO_0000694,severe acute respiratory syndrome,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4435170,DEUCRAVACITINIB,4.0,Completed,EFO_0000676,psoriasis,,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4596392,CRAVACITINIB,3.0,"Active, not recruiting",EFO_0000676,psoriasis,,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4459585,ROPSACITINIB,2.0,Completed,EFO_0000676,psoriasis,,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
Evasion by RSV of host interferon responses,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,TYK2,ENSG00000105397,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3A,ENSG00000105723,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3A,ENSG00000105723,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3A,ENSG00000105723,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3B,ENSG00000082701,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3B,ENSG00000082701,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3B,ENSG00000082701,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3B,ENSG00000082701,CHEMBL483465,ELRAGLUSIB,2.0,"Active, not recruiting",EFO_0000691,sarcoma,,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3
AKT phosphorylates targets in the cytosol,R-HSA-198323,https://reactome.org/PathwayBrowser/#/R-HSA-198323,GSK3B,ENSG00000082701,CHEMBL3545157,TIDEGLUSIB,2.0,Completed,EFO_0003756,autism spectrum disorder,,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1
XBP1(S) activates chaperone genes,R-HSA-381038,https://reactome.org/PathwayBrowser/#/R-HSA-381038,GSK3A,ENSG00000105723,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
XBP1(S) activates chaperone genes,R-HSA-381038,https://reactome.org/PathwayBrowser/#/R-HSA-381038,GSK3A,ENSG00000105723,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
XBP1(S) activates chaperone genes,R-HSA-381038,https://reactome.org/PathwayBrowser/#/R-HSA-381038,GSK3A,ENSG00000105723,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3A,ENSG00000105723,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3A,ENSG00000105723,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3A,ENSG00000105723,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3B,ENSG00000082701,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3B,ENSG00000082701,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3B,ENSG00000082701,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3B,ENSG00000082701,CHEMBL483465,ELRAGLUSIB,2.0,"Active, not recruiting",EFO_0000691,sarcoma,,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3
Constitutive Signaling by AKT1 E17K in Cancer,R-HSA-5674400,https://reactome.org/PathwayBrowser/#/R-HSA-5674400,GSK3B,ENSG00000082701,CHEMBL3545157,TIDEGLUSIB,2.0,Completed,EFO_0003756,autism spectrum disorder,,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1
Suppression of apoptosis,R-HSA-9635465,https://reactome.org/PathwayBrowser/#/R-HSA-9635465,GSK3A,ENSG00000105723,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
Suppression of apoptosis,R-HSA-9635465,https://reactome.org/PathwayBrowser/#/R-HSA-9635465,GSK3A,ENSG00000105723,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Suppression of apoptosis,R-HSA-9635465,https://reactome.org/PathwayBrowser/#/R-HSA-9635465,GSK3A,ENSG00000105723,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3A,ENSG00000105723,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3A,ENSG00000105723,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3A,ENSG00000105723,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3B,ENSG00000082701,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3B,ENSG00000082701,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3B,ENSG00000082701,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3B,ENSG00000082701,CHEMBL483465,ELRAGLUSIB,2.0,"Active, not recruiting",EFO_0000691,sarcoma,,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3
Maturation of nucleoprotein,R-HSA-9683610,https://reactome.org/PathwayBrowser/#/R-HSA-9683610,GSK3B,ENSG00000082701,CHEMBL3545157,TIDEGLUSIB,2.0,Completed,EFO_0003756,autism spectrum disorder,,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL25,ASPIRIN,4.0,,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL139,DICLOFENAC,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL421,SULFASALAZINE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,Completed,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL277474,ANTIPYRINE,4.0,,EFO_0003843,pain,,Cc1cc(=O)n(-c2ccccc2)n1C
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL94081,ALCLOFENAC,4.0,,EFO_0005755,rheumatic disease,,C=CCOc1ccc(CC(=O)O)cc1Cl
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005757,vaginal inflammation,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL461522,METAMIZOLE,3.0,Unknown status,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
COX reactions,R-HSA-140180,https://reactome.org/PathwayBrowser/#/R-HSA-140180,PTGS1,ENSG00000095303,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL25,ASPIRIN,4.0,,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL139,DICLOFENAC,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL421,SULFASALAZINE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,Completed,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL277474,ANTIPYRINE,4.0,,EFO_0003843,pain,,Cc1cc(=O)n(-c2ccccc2)n1C
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL94081,ALCLOFENAC,4.0,,EFO_0005755,rheumatic disease,,C=CCOc1ccc(CC(=O)O)cc1Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005757,vaginal inflammation,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL461522,METAMIZOLE,3.0,Unknown status,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS1,ENSG00000095303,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2162123,https://reactome.org/PathwayBrowser/#/R-HSA-2162123,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL294199,CAPSAICIN,4.0,,EFO_0003843,pain,,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL3707398,PAC-14028,3.0,Completed,EFO_0000274,atopic eczema,,
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL313971,ZUCAPSAICIN,3.0,Completed,EFO_0003843,pain,,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL3707356,TIVANISIRAN,3.0,Completed,EFO_1000906,dry eye syndrome,,
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL3707293,XEN-D0501,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL207433,SB-705498,2.0,Terminated,EFO_0000555,irritable bowel syndrome,,O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL3544953,SAF312,2.0,Completed,EFO_0003843,pain,,
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL3545039,AZD1386,2.0,Completed,EFO_0003843,pain,,Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL214796,NGD-8243,2.0,Completed,EFO_0003843,pain,,FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL5314400,DWP05195,2.0,Completed,MONDO_0041052,postherpetic neuralgia,,FC(F)(F)c1cccnc1-c1ccc(-c2nc3ccc(Br)cc3[nH]2)nc1
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL17976,RESINIFERATOXIN,1.0,Completed,EFO_0004616,"osteoarthritis, knee",,C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@@H]41)O2
TRP channels,R-HSA-3295583,https://reactome.org/PathwayBrowser/#/R-HSA-3295583,TRPV1,ENSG00000196689,CHEMBL2364618,MAVATREP,1.0,Completed,EFO_0004616,"osteoarthritis, knee",,CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL484785,CRISABOROLE,4.0,,EFO_0000274,atopic eczema,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL193240,ROFLUMILAST,4.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL514800,APREMILAST,4.0,,EFO_0000540,immune system disease,,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,4.0,,EFO_0003830,prostatitis,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL190,THEOPHYLLINE,4.0,,EFO_0006505,chronic bronchitis,,Cn1c(=O)c2[nH]cnc2n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL1096,AMLEXANOX,4.0,,HP_0006536,Airway obstruction,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL1752,DYPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL1200434,OXTRIPHYLLINE,4.0,,HP_0006536,Airway obstruction,,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL1370561,AMINOPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL3989968,DIFAMILAST,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL4594287,ENSIFENTRINE,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL511115,CILOMILAST,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL3113974,TRANIMILAST,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL332750,TETOMILAST,3.0,Completed,EFO_0000729,ulcerative colitis,,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL551978,DROTAVERINE,3.0,,EFO_0010282,gastrointestinal disease,,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL217899,TOFIMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL570015,GSK-256066,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL3989967,LOTAMILAST,2.0,Completed,EFO_0000274,atopic eczema,,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL4297520,OGLEMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL485629,MK-0873,2.0,Terminated,EFO_0000341,chronic obstructive pulmonary disease,,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL4297527,REVAMILAST,2.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL4297287,HT-0712,2.0,Completed,EFO_0001072,memory impairment,,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL4297460,DOVRAMILAST,2.0,Completed,EFO_0003834,cutaneous lupus erythematosus,,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL1493,FLAVOXATE,2.0,,HP_0000020,Urinary incontinence,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4A,ENSG00000065989,CHEMBL63,ROLIPRAM,2.0,Completed,MONDO_0005301,multiple sclerosis,,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL484785,CRISABOROLE,4.0,,EFO_0000274,atopic eczema,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL193240,ROFLUMILAST,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL514800,APREMILAST,4.0,,EFO_0000540,immune system disease,,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,4.0,,EFO_0003830,prostatitis,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL190,THEOPHYLLINE,4.0,,EFO_0006505,chronic bronchitis,,Cn1c(=O)c2[nH]cnc2n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL1200434,OXTRIPHYLLINE,4.0,,HP_0006536,Airway obstruction,,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL1096,AMLEXANOX,4.0,,HP_0006536,Airway obstruction,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL1370561,AMINOPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL1752,DYPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL3989968,DIFAMILAST,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL3113974,TRANIMILAST,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL511115,CILOMILAST,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL4594287,ENSIFENTRINE,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL332750,TETOMILAST,3.0,Completed,EFO_0000729,ulcerative colitis,,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL551978,DROTAVERINE,3.0,,EFO_0010282,gastrointestinal disease,,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL217899,TOFIMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL3989967,LOTAMILAST,2.0,Completed,EFO_0000274,atopic eczema,,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL4297520,OGLEMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL485629,MK-0873,2.0,Terminated,EFO_0000341,chronic obstructive pulmonary disease,,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL570015,GSK-256066,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL4297527,REVAMILAST,2.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL4297287,HT-0712,2.0,Completed,EFO_0001072,memory impairment,,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL4297460,DOVRAMILAST,2.0,Completed,EFO_0003834,cutaneous lupus erythematosus,,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL1493,FLAVOXATE,2.0,,HP_0000020,Urinary incontinence,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4B,ENSG00000184588,CHEMBL63,ROLIPRAM,2.0,Completed,MONDO_0005301,multiple sclerosis,,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL484785,CRISABOROLE,4.0,"Active, not recruiting",EFO_0000274,atopic eczema,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL193240,ROFLUMILAST,4.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL514800,APREMILAST,4.0,,EFO_0000540,immune system disease,,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,4.0,,EFO_0003901,dysuria,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL190,THEOPHYLLINE,4.0,,EFO_0006505,chronic bronchitis,,Cn1c(=O)c2[nH]cnc2n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL1096,AMLEXANOX,4.0,,HP_0006536,Airway obstruction,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL1370561,AMINOPHYLLINE,4.0,,MONDO_0004979,asthma,,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL1200434,OXTRIPHYLLINE,4.0,,HP_0006536,Airway obstruction,,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL1752,DYPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL3989968,DIFAMILAST,3.0,Completed,EFO_0000274,atopic eczema,,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL511115,CILOMILAST,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL3113974,TRANIMILAST,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL4594287,ENSIFENTRINE,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL332750,TETOMILAST,3.0,Completed,EFO_0000729,ulcerative colitis,,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL551978,DROTAVERINE,3.0,,EFO_0010282,gastrointestinal disease,,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL4541964,ZATOLMILAST,3.0,Enrolling by invitation,MONDO_0010383,fragile X syndrome,,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL217899,TOFIMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL4297520,OGLEMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL570015,GSK-256066,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL3989967,LOTAMILAST,2.0,Completed,EFO_0000274,atopic eczema,,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL485629,MK-0873,2.0,Terminated,EFO_0000341,chronic obstructive pulmonary disease,,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL4297527,REVAMILAST,2.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL4297287,HT-0712,2.0,Completed,EFO_0001072,memory impairment,,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL4297460,DOVRAMILAST,2.0,Completed,EFO_0003834,cutaneous lupus erythematosus,,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL1493,FLAVOXATE,2.0,,HP_0000103,Polyuria,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
DARPP-32 events,R-HSA-180024,https://reactome.org/PathwayBrowser/#/R-HSA-180024,PDE4D,ENSG00000113448,CHEMBL63,ROLIPRAM,2.0,Completed,MONDO_0005301,multiple sclerosis,,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL902,FAMOTIDINE,4.0,,EFO_0000685,rheumatoid arthritis,,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL2110372,RANITIDINE HYDROCHLORIDE,4.0,,EFO_0004607,duodenal ulcer,,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL30,CIMETIDINE,4.0,,EFO_0004607,duodenal ulcer,,CN/C(=N\CCSCc1nc[nH]c1C)NC#N
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL3183075,NIZATIDINE,4.0,,EFO_0004607,duodenal ulcer,,CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL1790041,RANITIDINE,4.0,,EFO_0003948,gastroesophageal reflux disease,,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL2111286,RANITIDINE BISMUTH CITRATE,4.0,,EFO_0003948,gastroesophageal reflux disease,,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3]
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL1201264,METHANTHELINE,4.0,,EFO_0010282,gastrointestinal disease,,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL1742461,LAFUTIDINE,3.0,Completed,EFO_0003948,gastroesophageal reflux disease,,O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,HRH2,ENSG00000113749,CHEMBL1200988,METHANTHELINE BROMIDE,1.0,Completed,HP_0000011,Neurogenic bladder,,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-]
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL484785,CRISABOROLE,4.0,,EFO_0000274,atopic eczema,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL193240,ROFLUMILAST,4.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL514800,APREMILAST,4.0,,EFO_0000540,immune system disease,,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,4.0,,EFO_0003830,prostatitis,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL190,THEOPHYLLINE,4.0,,EFO_0006505,chronic bronchitis,,Cn1c(=O)c2[nH]cnc2n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL1096,AMLEXANOX,4.0,,HP_0006536,Airway obstruction,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL1752,DYPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL1200434,OXTRIPHYLLINE,4.0,,HP_0006536,Airway obstruction,,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL1370561,AMINOPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL3989968,DIFAMILAST,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL4594287,ENSIFENTRINE,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL511115,CILOMILAST,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL3113974,TRANIMILAST,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL332750,TETOMILAST,3.0,Completed,EFO_0000729,ulcerative colitis,,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL551978,DROTAVERINE,3.0,,EFO_0010282,gastrointestinal disease,,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL217899,TOFIMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL570015,GSK-256066,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL3989967,LOTAMILAST,2.0,Completed,EFO_0000274,atopic eczema,,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL4297520,OGLEMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL485629,MK-0873,2.0,Terminated,EFO_0000341,chronic obstructive pulmonary disease,,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL4297527,REVAMILAST,2.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL4297287,HT-0712,2.0,Completed,EFO_0001072,memory impairment,,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL4297460,DOVRAMILAST,2.0,Completed,EFO_0003834,cutaneous lupus erythematosus,,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL1493,FLAVOXATE,2.0,,HP_0000020,Urinary incontinence,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4A,ENSG00000065989,CHEMBL63,ROLIPRAM,2.0,Completed,MONDO_0005301,multiple sclerosis,,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL484785,CRISABOROLE,4.0,"Active, not recruiting",EFO_0000274,atopic eczema,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL193240,ROFLUMILAST,4.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL514800,APREMILAST,4.0,,EFO_0000540,immune system disease,,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,4.0,,EFO_0003901,dysuria,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL190,THEOPHYLLINE,4.0,,EFO_0006505,chronic bronchitis,,Cn1c(=O)c2[nH]cnc2n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL1096,AMLEXANOX,4.0,,HP_0006536,Airway obstruction,,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL1370561,AMINOPHYLLINE,4.0,,MONDO_0004979,asthma,,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL1200434,OXTRIPHYLLINE,4.0,,HP_0006536,Airway obstruction,,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL1752,DYPHYLLINE,4.0,,HP_0006536,Airway obstruction,,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL3989968,DIFAMILAST,3.0,Completed,EFO_0000274,atopic eczema,,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL511115,CILOMILAST,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL3113974,TRANIMILAST,3.0,Recruiting,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL4594287,ENSIFENTRINE,3.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL332750,TETOMILAST,3.0,Completed,EFO_0000729,ulcerative colitis,,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL551978,DROTAVERINE,3.0,,EFO_0010282,gastrointestinal disease,,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL4541964,ZATOLMILAST,3.0,Enrolling by invitation,MONDO_0010383,fragile X syndrome,,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL217899,TOFIMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL4297520,OGLEMILAST,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL570015,GSK-256066,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL3989967,LOTAMILAST,2.0,Completed,EFO_0000274,atopic eczema,,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL485629,MK-0873,2.0,Terminated,EFO_0000341,chronic obstructive pulmonary disease,,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL4297527,REVAMILAST,2.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL4297287,HT-0712,2.0,Completed,EFO_0001072,memory impairment,,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL4297460,DOVRAMILAST,2.0,Completed,EFO_0003834,cutaneous lupus erythematosus,,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL1493,FLAVOXATE,2.0,,HP_0000103,Polyuria,,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
G alpha (s) signalling events,R-HSA-418555,https://reactome.org/PathwayBrowser/#/R-HSA-418555,PDE4D,ENSG00000113448,CHEMBL63,ROLIPRAM,2.0,Completed,MONDO_0005301,multiple sclerosis,,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1082407,ENZALUTAMIDE,4.0,Unknown status,EFO_0000196,metastatic prostate cancer,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL806,FLUTAMIDE,4.0,,EFO_0000313,carcinoma,,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL409,BICALUTAMIDE,4.0,,EFO_0000313,carcinoma,,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL2107067,TESTOSTERONE UNDECANOATE,4.0,,EFO_0000616,neoplasm,,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1200335,TESTOSTERONE ENANTHATE,4.0,,EFO_0000616,neoplasm,,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1201101,TESTOSTERONE CYPIONATE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1274,NILUTAMIDE,4.0,,EFO_0000616,neoplasm,,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1445,FLUOXYMESTERONE,4.0,,EFO_0000616,neoplasm,,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL386630,TESTOSTERONE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL4297185,DAROLUTAMIDE,4.0,,EFO_0000616,neoplasm,,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL254328,ABIRATERONE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3183409,APALUTAMIDE,4.0,"Active, not recruiting",EFO_0000673,prostate adenocarcinoma,,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1479,DANAZOL,4.0,,EFO_0001065,endometriosis,,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3590187,CLASCOTERONE,4.0,"Active, not recruiting",EFO_0003894,acne,,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1395,METHYLTESTOSTERONE,4.0,,MONDO_0002146,hypogonadism,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1200436,OXANDROLONE,3.0,Withdrawn,EFO_0000546,injury,,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL4594417,PRUXELUTAMIDE,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1738889,ENOBOSARM,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL4650276,SHR3680,3.0,"Active, not recruiting",MONDO_0008315,prostate cancer,,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL2105738,GALETERONE,3.0,Terminated,MONDO_0008315,prostate cancer,,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL2079587,STANOZOLOL,2.0,Not yet recruiting,EFO_0000198,myelodysplastic syndrome,,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3545092,CR 1447,2.0,Terminated,EFO_0000304,breast adenocarcinoma,,
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3542265,LY2452473,2.0,Terminated,EFO_0000284,benign prostatic hyperplasia,,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3264610,SEVITERONEL,2.0,Terminated,EFO_0000616,neoplasm,,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1200946,NANDROLONE DECANOATE,2.0,Completed,EFO_0003964,hip fracture,,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL5170587,VK5211,2.0,Completed,EFO_0003964,hip fracture,,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL128748,DIMETHYLCURCUMIN,2.0,Completed,EFO_0003894,acne,,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3545333,MK-0773,2.0,Completed,EFO_1000653,sarcopenia,,
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3545174,GSK2881078,2.0,Completed,HP_0004326,Cachexia,,
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3545046,GSK2849466,1.0,Completed,HP_0004326,Cachexia,,
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL1170,TESTOSTERONE PROPIONATE,1.0,Suspended,EFO_1001271,Atrophic Vaginitis,,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL3545237,HE3235,1.0,Completed,MONDO_0008315,prostate cancer,,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL37676,APC-100,1.0,Unknown status,MONDO_0008315,prostate cancer,,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,AR,ENSG00000169083,CHEMBL2346976,AZD3514,1.0,Completed,MONDO_0008315,prostate cancer,,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,Terminated,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,Completed,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,Not yet recruiting,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL846,CALCITRIOL,4.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1200666,CALCIPOTRIENE,4.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1042,CHOLECALCIFEROL,4.0,Recruiting,EFO_0003882,osteoporosis,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1200622,PARICALCITOL,4.0,Terminated,EFO_0003884,chronic kidney disease,,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL3544909,CALCIFEDIOL,4.0,,EFO_0003884,chronic kidney disease,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1200810,DOXERCALCIFEROL,4.0,,EFO_0003884,chronic kidney disease,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1536,ERGOCALCIFEROL,4.0,,EFO_0009451,hypoparathyroidism,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1908376,SEOCALCITOL,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1040,CALCIFEDIOL ANHYDROUS,3.0,Completed,EFO_0000612,myocardial infarction,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL3989862,PEFCALCITOL,3.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL1601669,ALFACALCIDOL,3.0,Completed,EFO_0003882,osteoporosis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL4297608,ELDECALCITOL,3.0,Completed,EFO_0003882,osteoporosis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL2105107,INECALCITOL,2.0,Unknown status,EFO_0000222,acute myeloid leukemia,,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL2104955,BECOCALCIDIOL,2.0,Completed,EFO_0000676,psoriasis,,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL2105705,LUNACALCIPOL,2.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL605525,DP001,2.0,Completed,EFO_0003882,osteoporosis,,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,VDR,ENSG00000111424,CHEMBL284121,ILX23-7553,1.0,Completed,EFO_0000616,neoplasm,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,Terminated,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,Completed,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,Not yet recruiting,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,,,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,Terminated,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,Completed,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,Not yet recruiting,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Nicotinamide salvaging,R-HSA-73614,https://reactome.org/PathwayBrowser/#/R-HSA-73614,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Synthesis of 15-eicosatetraenoic acid derivatives,R-HSA-2142770,https://reactome.org/PathwayBrowser/#/R-HSA-2142770,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Biosynthesis of DHA-derived SPMs,R-HSA-9018677,https://reactome.org/PathwayBrowser/#/R-HSA-9018677,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Biosynthesis of EPA-derived SPMs,R-HSA-9018679,https://reactome.org/PathwayBrowser/#/R-HSA-9018679,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Biosynthesis of DPAn-3 SPMs,R-HSA-9025094,https://reactome.org/PathwayBrowser/#/R-HSA-9025094,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL521,IBUPROFEN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)Cc1ccc(C(C)C(=O)O)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL6,INDOMETHACIN,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL25,ASPIRIN,4.0,Completed,EFO_0000612,myocardial infarction,,CC(=O)Oc1ccccc1C(=O)O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL118,CELECOXIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1034,DICLOFENAC SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1070,NABUMETONE,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc(CCC(C)=O)ccc2c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1200804,DICLOFENAC POTASSIUM,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL139,DICLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL154,NAPROXEN,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1562610,MECLOFENAMATE SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL421,SULFASALAZINE,4.0,Completed,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL599,MELOXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL865,VALDECOXIB,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1200760,BALSALAZIDE DISODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1201013,OLSALAZINE SODIUM,4.0,,EFO_0000729,ulcerative colitis,,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1071,OXAPROZIN,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL704,MESALAMINE,4.0,,EFO_0000729,ulcerative colitis,,Nc1ccc(O)c(C(=O)O)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1200613,TOLMETIN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1200806,NAPROXEN SODIUM,4.0,,EFO_0000685,rheumatoid arthritis,,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL15770,SULINDAC,4.0,,EFO_0000685,rheumatoid arthritis,,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL2103736,FENOPROFEN CALCIUM,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL527,PIROXICAM,4.0,,EFO_0000685,rheumatoid arthritis,,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL571,KETOPROFEN,4.0,,EFO_0000685,rheumatoid arthritis,,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL622,ETODOLAC,4.0,,EFO_0000685,rheumatoid arthritis,,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL898,DIFLUNISAL,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL93645,ACECLOFENAC,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1021,NEPAFENAC,4.0,,EFO_0003843,pain,,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL112,ACETAMINOPHEN,4.0,,EFO_0003843,pain,,CC(=O)Nc1ccc(O)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1201180,DICLOFENAC EPOLAMINE,4.0,,EFO_0003843,pain,,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL146095,GLAFENINE,4.0,,EFO_0003843,pain,,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL3989803,DIPYRONE,4.0,Completed,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1077,BROMFENAC,4.0,,EFO_0005752,eye inflammation,,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL3989676,OXYPHENBUTAZONE,4.0,,EFO_0005752,eye inflammation,,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL469,KETOROLAC,4.0,,EFO_0005752,eye inflammation,,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL563,FLURBIPROFEN,4.0,,EFO_0005752,eye inflammation,,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL101,PHENYLBUTAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL122,ROFECOXIB,4.0,,EFO_0005755,rheumatic disease,,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL12610,BENZYDAMINE,4.0,,EFO_0005755,rheumatic disease,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1297,FENOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL15870,INDOPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL175,DEXIBUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL189171,ACEMETACIN,4.0,,EFO_0005755,rheumatic disease,,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL416146,ETORICOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL686,MEFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL75435,DEXKETOPROFEN,4.0,,EFO_0005755,rheumatic disease,,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1201124,KETOROLAC TROMETHAMINE,4.0,,EFO_0003843,pain,,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL2108222,ALOXIPRIN,4.0,,EFO_0003843,pain,,
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL296913,PARECOXIB SODIUM,4.0,,EFO_0003843,pain,,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL3181947,BROMFENAC SODIUM,4.0,,EFO_0003843,pain,,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1020,TOLMETIN,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1206690,PARECOXIB,4.0,,EFO_0005755,rheumatic disease,,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1565476,APAZONE,4.0,,EFO_0005755,rheumatic disease,,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1569487,LORNOXICAM,4.0,,EFO_0005755,rheumatic disease,,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL188952,PIRPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL404108,LUMIRACOXIB,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL509,MECLOFENAMIC ACID,4.0,,EFO_0005755,rheumatic disease,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL956,SUPROFEN,4.0,,EFO_0005755,rheumatic disease,,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1120,BISMUTH SUBSALICYLATE,4.0,,HP_0002018,Nausea,,
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1201141,IBUPROFEN LYSINE,4.0,,HP_0001643,Patent ductus arteriosus,,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL2107455,IGURATIMOD,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL364804,GW-406381,3.0,Completed,EFO_0000685,rheumatoid arthritis,,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1201346,BALSALAZIDE,3.0,Completed,EFO_0000729,ulcerative colitis,,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL3989408,IBUPROFEN SODIUM,3.0,Completed,EFO_0003843,pain,,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL461522,METAMIZOLE,3.0,Recruiting,EFO_0003843,pain,,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL2103831,NAPROXCINOD,3.0,,EFO_0005755,rheumatic disease,,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL19299,LOXOPROFEN,3.0,Completed,EFO_0003843,pain,,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL166863,POLMACOXIB,3.0,Completed,EFO_1000786,"osteoarthritis, hip",,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,3.0,Not yet recruiting,EFO_1001904,oral mucositis,,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL435298,ESFLURBIPROFEN,3.0,Completed,HP_0030839,Knee pain,,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL1835207,APRICOXIB,2.0,Completed,EFO_0002618,pancreatic carcinoma,,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL425,OLSALAZINE,2.0,Completed,EFO_0003898,ankylosing spondylitis,,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL435381,CIMICOXIB,2.0,Completed,MONDO_0002050,depressive disorder,,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL2105683,NAPROXEN ETEMESIL,2.0,Completed,MONDO_0005178,osteoarthritis,,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1
Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,R-HSA-9027604,https://reactome.org/PathwayBrowser/#/R-HSA-9027604,PTGS2,ENSG00000073756,CHEMBL3989410,INDOMETHACIN SODIUM,1.0,Completed,MP_0001845,inflammation,,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200914,TAMSULOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL24778,SILODOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL611,TERAZOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL836,TAMSULOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201212,MIDODRINE,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc(OC)c(C(O)CNC(=O)CN)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201319,METARAMINOL,4.0,,EFO_0000319,cardiovascular disease,,C[C@H](N)[C@H](O)c1cccc(O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL524,METHOXAMINE,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc(OC)c(C(O)C(C)N)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200561,DOXAZOSIN MESYLATE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1723,ALFUZOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL3989562,TERAZOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL709,ALFUZOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1215,PHENYLEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1cccc(O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL723,CARVEDILOL,4.0,,EFO_0000319,cardiovascular disease,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1558,PRAZOSIN HYDROCHLORIDE,4.0,,EFO_0000400,diabetes mellitus,,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201167,CARVEDILOL PHOSPHATE,4.0,,EFO_0000537,hypertension,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2,PRAZOSIN,4.0,,EFO_0000537,hypertension,,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL707,DOXAZOSIN,4.0,Unknown status,EFO_0000537,hypertension,,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201044,DAPIPRAZOLE HYDROCHLORIDE,4.0,,EFO_0004190,open-angle glaucoma,,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200339,PHENYLEPHRINE HYDROCHLORIDE,4.0,,EFO_0006834,septic shock,,CNC[C@H](O)c1cccc(O)c1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0007214,common cold,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL12713,SERTINDOLE,4.0,,EFO_0005407,psychosis,,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2062264,PHENYLEPHRINE BITARTRATE,4.0,,EFO_0007214,common cold,,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL61006,PHENYLPROPANOLAMINE,4.0,,HP_0001742,Nasal congestion,,CC(N)C(O)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201216,DAPIPRAZOLE,4.0,,MONDO_0005041,glaucoma,,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL644,TRIMIPRAMINE,4.0,,MONDO_0002009,major depressive disorder,,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1200461,MIDODRINE HYDROCHLORIDE,3.0,Terminated,EFO_0006834,septic shock,,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2107546,BUCINDOLOL HYDROCHLORIDE,2.0,Completed,EFO_0000275,atrial fibrillation,,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL321582,BUCINDOLOL,2.0,Completed,EFO_0000275,atrial fibrillation,,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1197051,ISOXSUPRINE,2.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL1201103,METHOXAMINE HYDROCHLORIDE,2.0,Completed,EFO_0009523,fecal incontinence,,COc1ccc(OC)c(C(O)C(C)N)c1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL2104986,TEDATIOXETINE,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,ADRA1A,ENSG00000120907,CHEMBL559180,ISOXSUPRINE HYDROCHLORIDE,1.0,Completed,MONDO_0005301,multiple sclerosis,,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1069,VALSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1200692,OLMESARTAN MEDOXOMIL,4.0,,EFO_0000319,cardiovascular disease,,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1513,IRBESARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL408403,ANGIOTENSIN II,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL813,EPROSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL191,LOSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1014,CANDESARTAN CILEXETIL,4.0,,EFO_0000400,diabetes mellitus,,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1017,TELMISARTAN,4.0,,EFO_0000400,diabetes mellitus,,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL995,LOSARTAN POTASSIUM,4.0,Completed,EFO_0000537,hypertension,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+]
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1200987,EPROSARTAN MESYLATE,4.0,,EFO_0000537,hypertension,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,4.0,,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL539423,SPARSENTAN,4.0,,EFO_0004194,IGA glomerulonephritis,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL3989932,ANGIOTENSIN II ACETATE,4.0,,EFO_0005251,hypotension,,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1016,CANDESARTAN,3.0,Unknown status,EFO_0000266,aortic stenosis,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL2028661,AZILSARTAN MEDOXOMIL,3.0,,EFO_0000319,cardiovascular disease,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1951143,FIMASARTAN,3.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL1516,OLMESARTAN,3.0,Completed,EFO_0000275,atrial fibrillation,,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL57242,AZILSARTAN,3.0,Completed,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL432162,TASOSARTAN,2.0,,EFO_0000319,cardiovascular disease,,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,AGTR1,ENSG00000144891,CHEMBL4297447,TRV-120027,2.0,Completed,EFO_0003144,heart failure,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL1873475,IBRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3707348,ACALABRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4594293,ACALABRUTINIB MALEATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3936761,ZANUBRUTINIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL5314649,RITLECITINIB TOSYLATE,4.0,,EFO_0004192,alopecia areata,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4650485,PIRTOBRUTINIB,4.0,,EFO_1001469,Mantle cell lymphoma,,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4650321,ORELABRUTINIB,3.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4065122,FENEBRUTINIB,3.0,"Active, not recruiting",EFO_0003840,chronic progressive multiple sclerosis,,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4297865,ABIVERTINIB,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4085457,RITLECITINIB,3.0,Recruiting,EFO_0004208,Vitiligo,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4297866,ABIVERTINIB MALEATE,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4650323,TOLEBRUTINIB,3.0,Recruiting,EFO_0008520,primary progressive multiple sclerosis,,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3702854,RILZABRUTINIB,3.0,Recruiting,EFO_0007160,autoimmune thrombocytopenic purpura,,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4072833,EVOBRUTINIB,3.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4650338,EDRALBRUTINIB,2.0,Recruiting,EFO_0000096,neoplasm of mature B-cells,,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4071161,TIRABRUTINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3301600,SPEBRUTINIB BESYLATE,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3301625,SPEBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4163691,POSELTINIB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3900554,BMS-986142,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4594348,ELSUBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL4297674,BRANEBRUTINIB,1.0,Completed,EFO_0000685,rheumatoid arthritis,,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,BTK,ENSG00000010671,CHEMBL3545193,MSC-2364447,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,CYSLTR1,ENSG00000173198,CHEMBL787,MONTELUKAST,4.0,Unknown status,EFO_0003956,seasonal allergic rhinitis,,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,CYSLTR1,ENSG00000173198,CHEMBL1200681,MONTELUKAST SODIUM,4.0,,EFO_0005854,allergic rhinitis,,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+]
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,CYSLTR1,ENSG00000173198,CHEMBL603,ZAFIRLUKAST,4.0,,HP_0006536,Airway obstruction,,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,CYSLTR1,ENSG00000173198,CHEMBL21333,PRANLUKAST,3.0,Completed,EFO_0003956,seasonal allergic rhinitis,,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200750,PROMETHAZINE HYDROCHLORIDE,4.0,,EFO_0000274,atopic eczema,,CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201190,LEVOCETIRIZINE DIHYDROCHLORIDE,4.0,,EFO_0000701,skin disease,,Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200467,HYDROXYZINE PAMOATE,4.0,,EFO_0000701,skin disease,,O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1659,CHLORPHENIRAMINE MALEATE,4.0,,EFO_0003843,pain,,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200618,FEXOFENADINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200795,CLEMASTINE FUMARATE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200961,BROMPHENIRAMINE MALEATE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201006,PYRILAMINE MALEATE,4.0,,EFO_0003956,seasonal allergic rhinitis,,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1716,CYPROHEPTADINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1719,OLOPATADINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL3188034,TRIPROLIDINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl.O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL998,LORATADINE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1620,DIPHENHYDRAMINE HYDROCHLORIDE,4.0,,EFO_0003958,sunburn,,CN(C)CCOC(c1ccccc1)c1ccccc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1172,DESLORATADINE,4.0,Terminated,EFO_0005531,urticaria,,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1607273,CETIRIZINE HYDROCHLORIDE,4.0,,EFO_0005531,urticaria,,Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200927,DEXCHLORPHENIRAMINE MALEATE,4.0,,EFO_0005532,angioedema,,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1106,EPINASTINE,4.0,,EFO_0005751,eye allergy,,NC1=NCC2c3ccccc3Cc3ccccc3N12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201747,ALCAFTADINE,4.0,,EFO_0005751,eye allergy,,CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1742423,BILASTINE,4.0,,EFO_0005751,eye allergy,,CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL534,KETOTIFEN,4.0,,EFO_0005751,eye allergy,,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL639,AZELASTINE,4.0,,EFO_0005751,eye allergy,,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200809,AZELASTINE HYDROCHLORIDE,4.0,Completed,EFO_0005854,allergic rhinitis,,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201759,BEPOTASTINE BESYLATE,4.0,,EFO_0007141,allergic conjunctivitis,,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200638,DEXBROMPHENIRAMINE MALEATE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200974,CARBINOXAMINE MALEATE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL896,HYDROXYZINE,4.0,,EFO_0005230,anxiety,,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1000,CETIRIZINE,4.0,,EFO_0005751,eye allergy,,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1189432,OLOPATADINE,4.0,,EFO_0005751,eye allergy,,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1615438,LEVOCABASTINE,4.0,,EFO_0005751,eye allergy,,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL594,EMEDASTINE,4.0,,EFO_0005751,eye allergy,,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL3989555,MECLIZINE HYDROCHLORIDE,4.0,,EFO_0006928,motion sickness,,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1.Cl.Cl.O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200491,EPINASTINE HYDROCHLORIDE,4.0,,EFO_0007141,allergic conjunctivitis,,Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL2103739,EMEDASTINE DIFUMARATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1193,PHENIRAMINE,4.0,,HP_0000989,Pruritus,,CN(C)CCC(c1ccccc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1241,TRIPELENNAMINE,4.0,,HP_0000989,Pruritus,,CN(C)CCN(Cc1ccccc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL2105458,THENALIDINE,4.0,,HP_0000989,Pruritus,,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL2110774,CHLORPHENOXAMINE,4.0,,HP_0000989,Pruritus,,CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL643,PROMETHAZINE,4.0,,HP_0000989,Pruritus,,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL657,DIPHENHYDRAMINE,4.0,,HP_0000989,Pruritus,,CN(C)CCOC(c1ccccc1)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL24441,BETAHISTINE,4.0,,HP_0002321,Vertigo,,CNCCc1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL644,TRIMIPRAMINE,4.0,Unknown status,MONDO_0002050,depressive disorder,,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1626,CLEMASTINE,4.0,,HP_0000989,Pruritus,,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL511,PYRILAMINE,4.0,,HP_0000989,Pruritus,,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL43064,CINNARIZINE,4.0,,HP_0002321,Vertigo,,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200959,METHDILAZINE,4.0,,MONDO_0005271,allergic disease,,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201191,LEVOCETIRIZINE,4.0,,MONDO_0005271,allergic disease,,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201245,BROMODIPHENHYDRAMINE,4.0,,MONDO_0005271,allergic disease,,CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201271,BUCLIZINE,4.0,,MONDO_0005271,allergic disease,,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201287,DEXBROMPHENIRAMINE,4.0,,MONDO_0005271,allergic disease,,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1224,ACRIVASTINE,4.0,,MONDO_0005271,allergic disease,,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL13828,OXATOMIDE,4.0,,MONDO_0005271,allergic disease,,O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1411979,METHAPYRILENE,4.0,,MONDO_0005271,allergic disease,,CN(C)CCN(Cc1cccs1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1492,DIPHENYLPYRALINE,4.0,,MONDO_0005271,allergic disease,,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1623,MECLIZINE,4.0,,MONDO_0005271,allergic disease,,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL296419,ASTEMIZOLE,4.0,,MONDO_0005271,allergic disease,,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL505,CHLORPHENIRAMINE,4.0,,MONDO_0005271,allergic disease,,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL648,CYCLIZINE,4.0,,MONDO_0005271,allergic disease,,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL829,METHYLPROMAZINE,4.0,,MONDO_0005271,allergic disease,,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL855,TRIPROLIDINE,4.0,,MONDO_0005271,allergic disease,,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL864,CARBINOXAMINE,4.0,,MONDO_0005271,allergic disease,,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL914,FEXOFENADINE,4.0,,MONDO_0005271,allergic disease,,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1442422,DIBENZEPIN,4.0,,MONDO_0002009,major depressive disorder,,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200406,DIMENHYDRINATE,4.0,,MONDO_0005271,allergic disease,,CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL17157,TERFENADINE,4.0,,MONDO_0005271,allergic disease,,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL278398,PHENINDAMINE,4.0,,MONDO_0005271,allergic disease,,CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL516,CYPROHEPTADINE,4.0,,MONDO_0005271,allergic disease,,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL73451,MEQUITAZINE,4.0,,MONDO_0005271,allergic disease,,c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL811,BROMPHENIRAMINE,4.0,,MONDO_0005271,allergic disease,,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL94454,MIZOLASTINE,4.0,,MONDO_0005271,allergic disease,,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL946,AZATADINE,4.0,,MONDO_0005271,allergic disease,,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL90,HISTAMINE,3.0,Unknown status,EFO_0000389,cutaneous melanoma,,NCCc1c[nH]cn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL305660,EBASTINE,3.0,Recruiting,EFO_0000555,irritable bowel syndrome,,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL91397,RUPATADINE,3.0,Recruiting,EFO_0000685,rheumatoid arthritis,,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1653,PHENIRAMINE MALEATE,3.0,Completed,EFO_0000684,respiratory system disease,,CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1305,ANTAZOLINE,3.0,Unknown status,EFO_0000678,pterygium,,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1633,KETOTIFEN FUMARATE,3.0,"Active, not recruiting",EFO_0003931,bone fracture,,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL2107339,ESMIRTAZAPINE MALEATE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201353,DEXCHLORPHENIRAMINE,3.0,Unknown status,EFO_0003958,sunburn,,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1366933,ESMIRTAZAPINE,3.0,Completed,EFO_0004698,insomnia,,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201758,BEPOTASTINE,3.0,Completed,EFO_1001417,"Rhinitis, Allergic, Perennial",,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1237102,LEVOCABASTINE HYDROCHLORIDE,3.0,Completed,EFO_1001417,"Rhinitis, Allergic, Perennial",,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1004,DOXYLAMINE,3.0,Completed,HP_0002017,Nausea and vomiting,,CN(C)CCOC(C)(c1ccccc1)c1ccccn1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1200392,DOXYLAMINE SUCCINATE,3.0,Completed,HP_0002017,Nausea and vomiting,,CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1201089,DIPHENHYDRAMINE CITRATE,3.0,Completed,MONDO_0005277,migraine disorder,,CN(C)CCOC(c1ccccc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL5314393,LY2624803,2.0,Completed,EFO_0004698,insomnia,,CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL1767164,GSK-1004723,2.0,Completed,EFO_0003956,seasonal allergic rhinitis,,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
G alpha (q) signalling events,R-HSA-416476,https://reactome.org/PathwayBrowser/#/R-HSA-416476,HRH1,ENSG00000196639,CHEMBL22108,DIMETHINDENE,2.0,,HP_0000989,Pruritus,,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200914,TAMSULOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL24778,SILODOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL611,TERAZOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL836,TAMSULOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201212,MIDODRINE,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc(OC)c(C(O)CNC(=O)CN)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201234,MEPHENTERMINE,4.0,,EFO_0000319,cardiovascular disease,,CNC(C)(C)Cc1ccccc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201319,METARAMINOL,4.0,,EFO_0000319,cardiovascular disease,,C[C@H](N)[C@H](O)c1cccc(O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL211456,EPHEDRINE,4.0,,EFO_0000319,cardiovascular disease,,CN[C@@H](C)[C@H](O)c1ccccc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2311030,ERGOLOID MESYLATES,4.0,,EFO_0000319,cardiovascular disease,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL429,LABETALOL,4.0,,EFO_0000319,cardiovascular disease,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL524,METHOXAMINE,4.0,,EFO_0000319,cardiovascular disease,,COc1ccc(OC)c(C(O)C(C)N)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL679,EPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1ccc(O)c(O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200561,DOXAZOSIN MESYLATE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL753,PHENOXYBENZAMINE,4.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL770,TOLAZOLINE,4.0,,EFO_0000319,cardiovascular disease,,c1ccc(CC2=NCCN2)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1723,ALFUZOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL3989562,TERAZOSIN HYDROCHLORIDE,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL709,ALFUZOSIN,4.0,,EFO_0000284,benign prostatic hyperplasia,,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200873,PHENTOLAMINE MESYLATE,4.0,,EFO_0000239,adrenal gland pheochromocytoma,,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1215,PHENYLEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,CNC[C@H](O)c1cccc(O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1437,NOREPINEPHRINE,4.0,,EFO_0000319,cardiovascular disease,,NC[C@H](O)c1ccc(O)c(O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL159226,MOXISYLYTE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2103827,DROXIDOPA,4.0,,EFO_0000319,cardiovascular disease,,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL597,PHENTOLAMINE,4.0,,EFO_0000319,cardiovascular disease,,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL723,CARVEDILOL,4.0,,EFO_0000319,cardiovascular disease,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1558,PRAZOSIN HYDROCHLORIDE,4.0,,EFO_0000400,diabetes mellitus,,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201167,CARVEDILOL PHOSPHATE,4.0,,EFO_0000537,hypertension,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200323,LABETALOL HYDROCHLORIDE,4.0,,EFO_0000537,hypertension,,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2,PRAZOSIN,4.0,,EFO_0000537,hypertension,,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL3559672,RAUWOLFIA SERPENTINA,4.0,,EFO_0000537,hypertension,,
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL707,DOXAZOSIN,4.0,Unknown status,EFO_0000537,hypertension,,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1256958,EPINEPHRINE BITARTRATE,4.0,,EFO_0003843,pain,,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201044,DAPIPRAZOLE HYDROCHLORIDE,4.0,,EFO_0004190,open-angle glaucoma,,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,Cl.c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CN[C@@H](C)[C@H](O)c1ccccc1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1434513,NOREPINEPHRINE BITARTRATE,4.0,,EFO_0002497,acute hypotension,,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1523964,EPHEDRINE SULFATE,4.0,,EFO_0005251,hypotension,,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1266,TETRAHYDROZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL761,NAPHAZOLINE,4.0,,EFO_0005751,eye allergy,,c1ccc2c(CC3=NCCN3)cccc2c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL762,OXYMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200339,PHENYLEPHRINE HYDROCHLORIDE,4.0,,EFO_0006834,septic shock,,CNC[C@H](O)c1cccc(O)c1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,4.0,,EFO_0007214,common cold,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL12713,SERTINDOLE,4.0,,EFO_0005407,psychosis,,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL312448,XYLOMETAZOLINE,4.0,,EFO_0005751,eye allergy,,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2062264,PHENYLEPHRINE BITARTRATE,4.0,,EFO_0007214,common cold,,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL61006,PHENYLPROPANOLAMINE,4.0,,HP_0001742,Nasal congestion,,CC(N)C(O)c1ccccc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2448612,ERGOTAMINE TARTRATE,4.0,,HP_0002315,Headache,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201216,DAPIPRAZOLE,4.0,,MONDO_0005041,glaucoma,,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201262,DIPIVEFRIN,4.0,,MONDO_0005041,glaucoma,,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL644,TRIMIPRAMINE,4.0,,MONDO_0002009,major depressive disorder,,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL442,ERGOTAMINE,4.0,,MONDO_0005277,migraine disorder,,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,3.0,Unknown status,EFO_0000678,pterygium,,Cl.c1ccc2c(c1)CCCC2C1=NCCN1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1981592,AVIPTADIL,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1200461,MIDODRINE HYDROCHLORIDE,3.0,Terminated,EFO_0006834,septic shock,,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2107546,BUCINDOLOL HYDROCHLORIDE,2.0,Completed,EFO_0000275,atrial fibrillation,,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL321582,BUCINDOLOL,2.0,Completed,EFO_0000275,atrial fibrillation,,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1197051,ISOXSUPRINE,2.0,,EFO_0000319,cardiovascular disease,,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2364968,ERGOLOID,2.0,Completed,EFO_0004718,vascular dementia,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL1201103,METHOXAMINE HYDROCHLORIDE,2.0,Completed,EFO_0009523,fecal incontinence,,COc1ccc(OC)c(C(O)C(C)N)c1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL2104986,TEDATIOXETINE,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,ADRA1A,ENSG00000120907,CHEMBL559180,ISOXSUPRINE HYDROCHLORIDE,1.0,Completed,MONDO_0005301,multiple sclerosis,,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL1873475,IBRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3707348,ACALABRUTINIB,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4594293,ACALABRUTINIB MALEATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3936761,ZANUBRUTINIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL5314649,RITLECITINIB TOSYLATE,4.0,,EFO_0004192,alopecia areata,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4650485,PIRTOBRUTINIB,4.0,,EFO_1001469,Mantle cell lymphoma,,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4650321,ORELABRUTINIB,3.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4065122,FENEBRUTINIB,3.0,"Active, not recruiting",EFO_0003840,chronic progressive multiple sclerosis,,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4297865,ABIVERTINIB,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4085457,RITLECITINIB,3.0,Recruiting,EFO_0004208,Vitiligo,,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4297866,ABIVERTINIB MALEATE,3.0,Not yet recruiting,EFO_0003060,non-small cell lung carcinoma,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4650323,TOLEBRUTINIB,3.0,Recruiting,EFO_0008520,primary progressive multiple sclerosis,,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3702854,RILZABRUTINIB,3.0,Recruiting,EFO_0007160,autoimmune thrombocytopenic purpura,,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4072833,EVOBRUTINIB,3.0,Terminated,EFO_0003929,relapsing-remitting multiple sclerosis,,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4650338,EDRALBRUTINIB,2.0,Recruiting,EFO_0000096,neoplasm of mature B-cells,,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4071161,TIRABRUTINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3301600,SPEBRUTINIB BESYLATE,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3301625,SPEBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4163691,POSELTINIB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3900554,BMS-986142,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4594348,ELSUBRUTINIB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL4297674,BRANEBRUTINIB,1.0,Completed,EFO_0000685,rheumatoid arthritis,,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1
G alpha (12/13) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,BTK,ENSG00000010671,CHEMBL3545193,MSC-2364447,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL1201187,MARAVIROC,4.0,Completed,EFO_0000180,HIV-1 infection,,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL1255794,APLAVIROC,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL1668019,APLAVIROC HYDROCHLORIDE,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL82301,VICRIVIROC,3.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL2109343,LERONLIMAB,3.0,Suspended,MONDO_0100096,COVID-19,,
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL1951914,AZD5672,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL1649931,PF-232798,2.0,Completed,EFO_0000764,HIV infection,,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL2107384,VICRIVIROC MALEATE,2.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL1688243,INCB-9471,2.0,Completed,EFO_0000764,HIV infection,,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL2109342,HGS-1025,1.0,Withdrawn,EFO_0000729,ulcerative colitis,,
Binding and entry of HIV virion,R-HSA-173107,https://reactome.org/PathwayBrowser/#/R-HSA-173107,CCR5,ENSG00000160791,CHEMBL2109341,CCR5MAB004,1.0,Completed,EFO_0000764,HIV infection,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL3545221,AZD2423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL3707228,PLOZALIZUMAB,2.0,Withdrawn,EFO_0000319,cardiovascular disease,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL2178573,ILACIRNON,2.0,Completed,EFO_0000401,diabetic nephropathy,,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL4297538,MK-0812,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL4650501,PF-4136309,2.0,Terminated,EFO_0004220,chronic hepatitis C virus infection,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL4457723,BMS-741672,2.0,Completed,EFO_0005762,neuropathic pain,,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR2,ENSG00000121807,CHEMBL2204263,JNJ-41443532,2.0,Completed,MONDO_0005148,type 2 diabetes mellitus,,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL1201187,MARAVIROC,4.0,Completed,EFO_0000180,HIV-1 infection,,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL1255794,APLAVIROC,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL1668019,APLAVIROC HYDROCHLORIDE,3.0,Terminated,EFO_0000764,HIV infection,,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL82301,VICRIVIROC,3.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL2110727,CENICRIVIROC,3.0,Terminated,EFO_1001249,non-alcoholic steatohepatitis,,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL2109343,LERONLIMAB,3.0,Suspended,MONDO_0100096,COVID-19,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL4594419,BMS-813160,2.0,Terminated,EFO_0000401,diabetic nephropathy,,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL5095029,PF-04634817,2.0,Completed,EFO_0000401,diabetic nephropathy,,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL1951914,AZD5672,2.0,Completed,EFO_0000685,rheumatoid arthritis,,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL1649931,PF-232798,2.0,Completed,EFO_0000764,HIV infection,,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL2107384,VICRIVIROC MALEATE,2.0,Completed,EFO_0000764,HIV infection,,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL1688243,INCB-9471,2.0,Completed,EFO_0000764,HIV infection,,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL2109342,HGS-1025,1.0,Withdrawn,EFO_0000729,ulcerative colitis,,
Chemokine receptors bind chemokines,R-HSA-380108,https://reactome.org/PathwayBrowser/#/R-HSA-380108,CCR5,ENSG00000160791,CHEMBL2109341,CCR5MAB004,1.0,Completed,EFO_0000764,HIV infection,,
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
EPHB-mediated forward signaling,R-HSA-3928662,https://reactome.org/PathwayBrowser/#/R-HSA-3928662,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
"Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-438066,https://reactome.org/PathwayBrowser/#/R-HSA-438066,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
Ras activation upon Ca2+ influx through NMDA receptor,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2,ENSG00000164400,CHEMBL3039547,PEXASTIMOGENE DEVACIREPVEC,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2,ENSG00000164400,CHEMBL2109433,OTILIMAB,3.0,Completed,EFO_0000685,rheumatoid arthritis,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2,ENSG00000164400,CHEMBL3707325,LENZILUMAB,3.0,"Active, not recruiting",EFO_0003106,pneumonia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2,ENSG00000164400,CHEMBL1743044,NAMILUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2,ENSG00000164400,CHEMBL4650518,PLONMARLIMAB,2.0,Completed,MONDO_0100096,COVID-19,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2,ENSG00000164400,CHEMBL2109430,GIMSILUMAB,2.0,Completed,MONDO_0100096,COVID-19,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3655081,ABROCITINIB,4.0,,EFO_0000274,atopic eczema,,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3622821,UPADACITINIB,3.0,Completed,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4297477,BREPOCITINIB,3.0,Recruiting,EFO_0000398,dermatomyositis,,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3622820,ITACITINIB,3.0,,EFO_0000540,immune system disease,,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4577523,GOLIDOCITINIB,2.0,Recruiting,EFO_0000211,unspecified peripheral T-cell lymphoma,,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3301606,SOLCITINIB,2.0,Completed,EFO_0000676,psoriasis,,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL3545225,INCB-047986,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4116008,CERDULATINIB,2.0,Completed,EFO_0004208,Vitiligo,,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK1,ENSG00000162434,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1421,DASATINIB,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000616,neoplasm,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Unknown status,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2109325,AMG-191,1.0,Recruiting,MONDO_0015974,severe combined immunodeficiency,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,,EFO_0000616,neoplasm,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
Neurexins and neuroligins,R-HSA-6794361,https://reactome.org/PathwayBrowser/#/R-HSA-6794361,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
Synaptic adhesion-like molecules,R-HSA-8849932,https://reactome.org/PathwayBrowser/#/R-HSA-8849932,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
Negative regulation of NMDA receptor-mediated neuronal transmission,R-HSA-9617324,https://reactome.org/PathwayBrowser/#/R-HSA-9617324,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1094,FELBAMATE,4.0,,EFO_0000474,epilepsy,,NC(=O)OCC(COC(N)=O)c1ccccc1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1569,AMANTADINE HYDROCHLORIDE,4.0,,EFO_0000544,infection,,Cl.NC12CC3CC(CC(C3)C1)C2
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1200395,ORPHENADRINE CITRATE,4.0,,EFO_0003843,pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1699,MEMANTINE HYDROCHLORIDE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL395091,ESKETAMINE,4.0,,MONDO_0002050,depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,4.0,,MONDO_0002009,major depressive disorder,,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL807,MEMANTINE,4.0,,HP_0000726,Dementia,,CC12CC3CC(C)(C1)CC(N)(C3)C2
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,4.0,,MONDO_0005180,Parkinson disease,,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL660,AMANTADINE,4.0,,MONDO_0005180,Parkinson disease,,NC12CC3CC(CC(C3)C1)C2
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1201293,ACAMPROSATE,4.0,Completed,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL2068724,ACAMPROSATE CALCIUM,4.0,,MONDO_0007079,alcohol dependence,,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1714,KETAMINE HYDROCHLORIDE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL742,KETAMINE,3.0,"Active, not recruiting",EFO_0000546,injury,,CNC1(c2ccccc2Cl)CCCCC1=O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL3545351,AV-101,3.0,"Active, not recruiting",EFO_0001361,pulmonary arterial hypertension,,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL2107771,RALFINAMIDE,3.0,Completed,EFO_0003843,pain,,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL2106798,NERAMEXANE MESYLATE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL3544917,RAPASTINEL,3.0,Terminated,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL2110954,NERAMEXANE,3.0,Completed,HP_0000360,Tinnitus,,CC1(C)CC(C)(C)CC(C)(N)C1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL900,ORPHENADRINE,3.0,Unknown status,HP_0003419,Low back pain,,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL17350,TRAXOPRODIL,2.0,Terminated,EFO_0000712,stroke,,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL1207366,GW468816,2.0,Completed,EFO_0003768,nicotine dependence,,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL182066,RADIPRODIL,2.0,Completed,EFO_0005762,neuropathic pain,,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL3707400,INDANTADOL,2.0,Completed,EFO_0005762,neuropathic pain,,
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL2068839,RISLENEMDAZ,2.0,Completed,MONDO_0002009,major depressive disorder,,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL3989872,APIMOSTINEL,2.0,Completed,MONDO_0002009,major depressive disorder,,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL467084,LANICEMINE,2.0,Completed,MONDO_0002009,major depressive disorder,,N[C@@H](Cc1ccccn1)c1ccccc1
Long-term potentiation,R-HSA-9620244,https://reactome.org/PathwayBrowser/#/R-HSA-9620244,GRIN1,ENSG00000176884,CHEMBL3545350,EVT-101,2.0,Terminated,MONDO_0002050,depressive disorder,,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,IL6R,ENSG00000160712,CHEMBL2108730,SARILUMAB,4.0,,EFO_0000540,immune system disease,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,IL6R,ENSG00000160712,CHEMBL3833307,SATRALIZUMAB,4.0,,EFO_0000540,immune system disease,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,IL6R,ENSG00000160712,CHEMBL1237022,TOCILIZUMAB,4.0,,EFO_0000540,immune system disease,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,IL6R,ENSG00000160712,CHEMBL4650406,LEVILIMAB,3.0,"Active, not recruiting",EFO_0000685,rheumatoid arthritis,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,IL6R,ENSG00000160712,CHEMBL3833343,VOBARILIZUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1069,VALSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1200692,OLMESARTAN MEDOXOMIL,4.0,,EFO_0000319,cardiovascular disease,,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1513,IRBESARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL408403,ANGIOTENSIN II,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL813,EPROSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL191,LOSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1014,CANDESARTAN CILEXETIL,4.0,,EFO_0000400,diabetes mellitus,,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1017,TELMISARTAN,4.0,,EFO_0000400,diabetes mellitus,,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL995,LOSARTAN POTASSIUM,4.0,Completed,EFO_0000537,hypertension,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+]
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1200987,EPROSARTAN MESYLATE,4.0,,EFO_0000537,hypertension,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,4.0,,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL539423,SPARSENTAN,4.0,,EFO_0004194,IGA glomerulonephritis,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL3989932,ANGIOTENSIN II ACETATE,4.0,,EFO_0005251,hypotension,,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1016,CANDESARTAN,3.0,Unknown status,EFO_0000266,aortic stenosis,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL2028661,AZILSARTAN MEDOXOMIL,3.0,,EFO_0000319,cardiovascular disease,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1951143,FIMASARTAN,3.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL1516,OLMESARTAN,3.0,Completed,EFO_0000275,atrial fibrillation,,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL57242,AZILSARTAN,3.0,Completed,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL432162,TASOSARTAN,2.0,,EFO_0000319,cardiovascular disease,,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,AGTR1,ENSG00000144891,CHEMBL4297447,TRV-120027,2.0,Completed,EFO_0003144,heart failure,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL1201828,ECULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL3989986,RAVULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL5315048,ZILUCOPLAN SODIUM,4.0,,EFO_0004991,Myasthenia gravis,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL4298086,POZELIMAB,4.0,,HP_0002243,Protein-losing enteropathy,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL2107979,PEXELIZUMAB,3.0,Completed,EFO_0001645,coronary artery disease,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL4298207,ZILUCOPLAN,3.0,Completed,EFO_0004991,Myasthenia gravis,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL4594316,CROVALIMAB,3.0,Withdrawn,EFO_0007292,Guillain-Barre syndrome,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL4297722,CEMDISIRAN,3.0,Recruiting,EFO_0004991,Myasthenia gravis,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL4297928,NOMACOPAN,3.0,Withdrawn,EFO_0007187,bullous pemphigoid,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL2109636,VILOBELIMAB,3.0,Recruiting,HP_0000999,Pyoderma,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL4298012,TESIDOLUMAB,2.0,Completed,EFO_0001365,age-related macular degeneration,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,C5,ENSG00000106804,CHEMBL3990025,OLENDALIZUMAB,2.0,Terminated,EFO_0002689,antiphospholipid syndrome,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2159122,ELUXADOLINE,4.0,,EFO_0000555,irritable bowel syndrome,,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL596,FENTANYL,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL607,MEPERIDINE,4.0,,EFO_0003843,pain,,CCOC(=O)C1(c2ccccc2)CCN(C)CC1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL651,METHADONE,4.0,,EFO_0003843,pain,,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL656,OXYCODONE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL688,FENTANYL CITRATE,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL70,MORPHINE,4.0,Completed,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL895,NALBUPHINE,4.0,Unknown status,EFO_0003843,pain,,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1200794,OXYMORPHONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1200825,METHADONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1200890,OXYCODONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201132,NALBUPHINE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201149,NALTREXONE HYDROCHLORIDE,4.0,Terminated,EFO_0003843,pain,,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201163,SUFENTANIL CITRATE,4.0,,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1237044,TRAMADOL,4.0,Recruiting,EFO_0003843,pain,,COc1cccc(C2(O)CCCCC2CN(C)C)c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1237055,HYDROMORPHONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1237065,TRAMADOL HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1237104,PROPOXYPHENE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1595,DIHYDROCODEINE,4.0,Completed,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1685,DEZOCINE,4.0,,EFO_0003843,pain,,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1701,MEPERIDINE HYDROCHLORIDE,4.0,Unknown status,EFO_0003843,pain,,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1718,NALOXONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2062266,DIHYDROCODEINE BITARTRATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2103744,MORPHINE SULFATE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2219416,NALOXEGOL OXALATE,4.0,,EFO_0003843,pain,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2443262,OLICERIDINE,4.0,,EFO_0003843,pain,,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3137310,BENZHYDROCODONE HYDROCHLORIDE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3833389,DEXTROMORAMIDE,4.0,,EFO_0003843,pain,,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL398707,HYDROMORPHONE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3989677,HYDROCODONE BITARTRATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL4297091,CODEINE SULFATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL485,CODEINE,4.0,Unknown status,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL511142,BUPRENORPHINE,4.0,Completed,EFO_0003843,pain,,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201099,CODEINE PHOSPHATE,4.0,,EFO_0003890,drug dependence,,
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2368861,BUPRENORPHINE HYDROCHLORIDE,4.0,,EFO_0003890,drug dependence,,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201770,METHYLNALTREXONE BROMIDE,4.0,,EFO_0005611,opioid dependence,,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1514,LEVOMETHADYL ACETATE,4.0,,EFO_0005611,opioid dependence,,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201776,TAPENTADOL,4.0,,EFO_0003843,pain,,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201777,TAPENTADOL HYDROCHLORIDE,4.0,,EFO_0003843,pain,,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1213351,PROPOXYPHENE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL963,OXYMORPHONE,4.0,,EFO_0003843,pain,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3039508,NALDEMEDINE TOSYLATE,4.0,,EFO_0003843,pain,,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL314437,MEPTAZINOL,4.0,,EFO_0003843,pain,,CCC1(c2cccc(O)c2)CCCCN(C)C1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL33986,BUTORPHANOL,4.0,,EFO_0003843,pain,,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3989716,PROPOXYPHENE NAPSYLATE,4.0,,EFO_0003843,pain,,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3989826,OXYCODONE TEREPHTHALATE,4.0,,EFO_0003843,pain,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL299400,BUTORPHANOL TARTRATE,4.0,,EFO_0003890,drug dependence,,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL5315056,NALOXONE HYDROCHLORIDE DIHYDRATE,4.0,,EFO_0005611,opioid dependence,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2219418,NALOXEGOL,4.0,Terminated,HP_0002019,Constipation,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL270190,ALVIMOPAN,4.0,,HP_0002019,Constipation,,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL80,NALOXONE,4.0,,HP_0002019,Constipation,,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1707,LOPERAMIDE HYDROCHLORIDE,4.0,Completed,HP_0002014,Diarrhea,,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2105749,SAMIDORPHAN L-MALATE,4.0,,EFO_0009963,bipolar I disorder,,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2105755,NALDEMEDINE,4.0,,HP_0002019,Constipation,,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1457,HYDROCODONE,4.0,,HP_0012735,Cough,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL19019,NALTREXONE,4.0,Completed,MONDO_0002046,alcohol abuse,,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL5315055,NALMEFENE HYDROCHLORIDE DIHYDRATE,4.0,,MONDO_0007079,alcohol dependence,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL982,NALMEFENE,4.0,Terminated,MONDO_0007079,alcohol dependence,,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL658,SUFENTANIL,3.0,Completed,EFO_0000546,injury,,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1005,REMIFENTANIL,3.0,Completed,EFO_0000616,neoplasm,,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1186579,METHYLNALTREXONE,3.0,Withdrawn,EFO_0002618,pancreatic carcinoma,,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL841,LOPERAMIDE,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2364605,CEBRANOPADOL,3.0,Not yet recruiting,EFO_0003843,pain,,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL459324,DIACETYLMORPHINE,3.0,Completed,EFO_0005611,opioid dependence,,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201159,FENTANYL HYDROCHLORIDE,3.0,Completed,EFO_0003843,pain,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3039511,BEVENOPRAN,3.0,Terminated,HP_0002019,Constipation,,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL4297632,OXYCODEGOL,3.0,Completed,HP_0003419,Low back pain,,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1200665,DIPHENOXYLATE HYDROCHLORIDE,2.0,Completed,EFO_0000304,breast adenocarcinoma,,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL1201294,DIPHENOXYLATE,2.0,Completed,EFO_0000304,breast adenocarcinoma,,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL4594402,ORP-101,2.0,Completed,EFO_0000555,irritable bowel syndrome,,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL4297383,GSK-1521498,2.0,Completed,EFO_0001073,obesity,,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3219616,CP-866087,2.0,Completed,EFO_0001073,obesity,,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2103829,FAXELADOL,2.0,Completed,EFO_0005687,fibromyalgia,,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL426084,SAMIDORPHAN,2.0,Completed,EFO_0005203,eating disorder,,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2364619,METHYLSAMIDORPHAN,2.0,Completed,HP_0002019,Constipation,,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3137313,AXELOPRAN,2.0,Completed,HP_0002019,Constipation,,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL3989680,AXOMADOL,2.0,Completed,HP_0003419,Low back pain,,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL2103878,ODELEPRAN,2.0,Completed,MONDO_0007079,alcohol dependence,,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1
Peptide ligand-binding receptors,R-HSA-375276,https://reactome.org/PathwayBrowser/#/R-HSA-375276,OPRM1,ENSG00000112038,CHEMBL592,LEVORPHANOL,0.5,"Active, not recruiting",EFO_0003843,pain,,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1069,VALSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1200692,OLMESARTAN MEDOXOMIL,4.0,,EFO_0000319,cardiovascular disease,,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1513,IRBESARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL408403,ANGIOTENSIN II,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL813,EPROSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL191,LOSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1014,CANDESARTAN CILEXETIL,4.0,,EFO_0000400,diabetes mellitus,,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1017,TELMISARTAN,4.0,,EFO_0000400,diabetes mellitus,,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL995,LOSARTAN POTASSIUM,4.0,Completed,EFO_0000537,hypertension,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+]
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1200987,EPROSARTAN MESYLATE,4.0,,EFO_0000537,hypertension,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,4.0,,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL539423,SPARSENTAN,4.0,,EFO_0004194,IGA glomerulonephritis,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL3989932,ANGIOTENSIN II ACETATE,4.0,,EFO_0005251,hypotension,,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1016,CANDESARTAN,3.0,Unknown status,EFO_0000266,aortic stenosis,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL2028661,AZILSARTAN MEDOXOMIL,3.0,,EFO_0000319,cardiovascular disease,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1951143,FIMASARTAN,3.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL1516,OLMESARTAN,3.0,Completed,EFO_0000275,atrial fibrillation,,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL57242,AZILSARTAN,3.0,Completed,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL432162,TASOSARTAN,2.0,,EFO_0000319,cardiovascular disease,,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2
Cargo recognition for clathrin-mediated endocytosis,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,AGTR1,ENSG00000144891,CHEMBL4297447,TRV-120027,2.0,Completed,EFO_0003144,heart failure,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1069,VALSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1200692,OLMESARTAN MEDOXOMIL,4.0,,EFO_0000319,cardiovascular disease,,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1513,IRBESARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL408403,ANGIOTENSIN II,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL813,EPROSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL191,LOSARTAN,4.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1014,CANDESARTAN CILEXETIL,4.0,,EFO_0000400,diabetes mellitus,,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1017,TELMISARTAN,4.0,,EFO_0000400,diabetes mellitus,,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL995,LOSARTAN POTASSIUM,4.0,Completed,EFO_0000537,hypertension,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+]
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1200987,EPROSARTAN MESYLATE,4.0,,EFO_0000537,hypertension,,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,4.0,,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL539423,SPARSENTAN,4.0,,EFO_0004194,IGA glomerulonephritis,,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL3989932,ANGIOTENSIN II ACETATE,4.0,,EFO_0005251,hypotension,,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1016,CANDESARTAN,3.0,Unknown status,EFO_0000266,aortic stenosis,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL2028661,AZILSARTAN MEDOXOMIL,3.0,,EFO_0000319,cardiovascular disease,,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1951143,FIMASARTAN,3.0,,EFO_0000319,cardiovascular disease,,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL1516,OLMESARTAN,3.0,Completed,EFO_0000275,atrial fibrillation,,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL57242,AZILSARTAN,3.0,Completed,EFO_0000537,hypertension,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL432162,TASOSARTAN,2.0,,EFO_0000319,cardiovascular disease,,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2
Clathrin-mediated endocytosis,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,AGTR1,ENSG00000144891,CHEMBL4297447,TRV-120027,2.0,Completed,EFO_0003144,heart failure,,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL1743034,IXEKIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL1743068,SECUKINUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL4297700,BIMEKIZUMAB,4.0,,EFO_0000540,immune system disease,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL4298102,VUNAKIZUMAB,3.0,Not yet recruiting,EFO_0000676,psoriasis,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL4298023,M-1095,3.0,Recruiting,EFO_1000710,hidradenitis suppurativa,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL4297686,IZOKIBEP,3.0,"Active, not recruiting",EFO_1000710,hidradenitis suppurativa,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL4297863,REMTOLUMAB,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL3990000,TIBULIZUMAB,2.0,Withdrawn,EFO_0000699,Sjogren syndrome,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL4297926,CJM-112,2.0,Completed,EFO_0003894,acne,,
Interleukin-17 signaling,R-HSA-448424,https://reactome.org/PathwayBrowser/#/R-HSA-448424,IL17A,ENSG00000112115,CHEMBL2109470,PERAKIZUMAB,1.0,Completed,EFO_0003778,psoriatic arthritis,,
Caspase activation via Death Receptors in the presence of ligand,R-HSA-140534,https://reactome.org/PathwayBrowser/#/R-HSA-140534,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
Regulation by c-FLIP,R-HSA-3371378,https://reactome.org/PathwayBrowser/#/R-HSA-3371378,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
RIPK1-mediated regulated necrosis,R-HSA-5213460,https://reactome.org/PathwayBrowser/#/R-HSA-5213460,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
CASP8 activity is inhibited,R-HSA-5218900,https://reactome.org/PathwayBrowser/#/R-HSA-5218900,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
Dimerization of procaspase-8,R-HSA-69416,https://reactome.org/PathwayBrowser/#/R-HSA-69416,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
FasL/ CD95L signaling,R-HSA-75157,https://reactome.org/PathwayBrowser/#/R-HSA-75157,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,R-HSA-8862803,https://reactome.org/PathwayBrowser/#/R-HSA-8862803,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
FOXO-mediated transcription of cell death genes,R-HSA-9614657,https://reactome.org/PathwayBrowser/#/R-HSA-9614657,FASLG,ENSG00000117560,CHEMBL4297886,ASUNERCEPT,3.0,Terminated,MONDO_0100096,COVID-19,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297564,COBITOLIMOD,3.0,Completed,EFO_0000729,ulcerative colitis,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL2103792,AGATOLIMOD,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297838,TILSOTOLIMOD,3.0,Terminated,EFO_0002617,metastatic melanoma,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL2103793,AGATOLIMOD SODIUM,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297680,1018 ISS,3.0,Terminated,MONDO_0100096,COVID-19,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297776,LEFITOLIMOD,2.0,Completed,EFO_0000180,HIV-1 infection,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297993,EMD-1201081,2.0,Completed,EFO_0000681,renal cell carcinoma,,
Trafficking and processing of endosomal TLR,R-HSA-1679131,https://reactome.org/PathwayBrowser/#/R-HSA-1679131,TLR9,ENSG00000239732,CHEMBL4297994,TILSOTOLIMOD SODIUM,2.0,Completed,EFO_0002617,metastatic melanoma,,
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
Toll Like Receptor 7/8 (TLR7/8) Cascade,R-HSA-168181,https://reactome.org/PathwayBrowser/#/R-HSA-168181,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
Regulation of TLR by endogenous ligand,R-HSA-5686938,https://reactome.org/PathwayBrowser/#/R-HSA-5686938,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
SARS-CoV-1 activates/modulates innate immune responses,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297564,COBITOLIMOD,3.0,Completed,EFO_0000729,ulcerative colitis,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL2103792,AGATOLIMOD,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297838,TILSOTOLIMOD,3.0,Terminated,EFO_0002617,metastatic melanoma,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL2103793,AGATOLIMOD SODIUM,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297680,1018 ISS,3.0,Terminated,MONDO_0100096,COVID-19,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297776,LEFITOLIMOD,2.0,Completed,EFO_0000180,HIV-1 infection,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297993,EMD-1201081,2.0,Completed,EFO_0000681,renal cell carcinoma,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,TLR9,ENSG00000239732,CHEMBL4297994,TILSOTOLIMOD SODIUM,2.0,Completed,EFO_0002617,metastatic melanoma,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297564,COBITOLIMOD,3.0,Completed,EFO_0000729,ulcerative colitis,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL2103792,AGATOLIMOD,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297838,TILSOTOLIMOD,3.0,Terminated,EFO_0002617,metastatic melanoma,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL2103793,AGATOLIMOD SODIUM,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297680,1018 ISS,3.0,Terminated,MONDO_0100096,COVID-19,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297776,LEFITOLIMOD,2.0,Completed,EFO_0000180,HIV-1 infection,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297993,EMD-1201081,2.0,Completed,EFO_0000681,renal cell carcinoma,,
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,R-HSA-975138,https://reactome.org/PathwayBrowser/#/R-HSA-975138,TLR9,ENSG00000239732,CHEMBL4297994,TILSOTOLIMOD SODIUM,2.0,Completed,EFO_0002617,metastatic melanoma,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297564,COBITOLIMOD,3.0,Completed,EFO_0000729,ulcerative colitis,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL2103792,AGATOLIMOD,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297838,TILSOTOLIMOD,3.0,Terminated,EFO_0002617,metastatic melanoma,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL2103793,AGATOLIMOD SODIUM,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297680,1018 ISS,3.0,Terminated,MONDO_0100096,COVID-19,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297776,LEFITOLIMOD,2.0,Completed,EFO_0000180,HIV-1 infection,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297993,EMD-1201081,2.0,Completed,EFO_0000681,renal cell carcinoma,,
MyD88 dependent cascade initiated on endosome,R-HSA-975155,https://reactome.org/PathwayBrowser/#/R-HSA-975155,TLR9,ENSG00000239732,CHEMBL4297994,TILSOTOLIMOD SODIUM,2.0,Completed,EFO_0002617,metastatic melanoma,,
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
Defective regulation of TLR7 by endogenous ligand,R-HSA-9824856,https://reactome.org/PathwayBrowser/#/R-HSA-9824856,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,4.0,,EFO_0000685,rheumatoid arthritis,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL1535,HYDROXYCHLOROQUINE,4.0,,EFO_0001068,malaria,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL1282,IMIQUIMOD,4.0,,EFO_0000763,viral disease,,CC(C)Cn1cnc2c(N)nc3ccccc3c21
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL2424780,VESATOLIMOD,2.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL4802159,ENPATORAN,2.0,Recruiting,EFO_0000398,dermatomyositis,,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL549344,CPG-52852,2.0,Completed,EFO_0000389,cutaneous melanoma,,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL4297995,BAZLITORAN,2.0,Completed,EFO_0000398,dermatomyositis,,
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL383322,RESIQUIMOD,2.0,"Active, not recruiting",EFO_0000632,oligodendroglioma,,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL4297492,GSK-2245035,2.0,Completed,EFO_0010638,atopic asthma,,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL4297356,AZD-8848,2.0,Completed,EFO_0005854,allergic rhinitis,,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1
RSV-host interactions,R-HSA-9833110,https://reactome.org/PathwayBrowser/#/R-HSA-9833110,TLR7,ENSG00000196664,CHEMBL4297631,TELRATOLIMOD,1.0,"Active, not recruiting",EFO_0000180,HIV-1 infection,,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1421,DASATINIB,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000616,neoplasm,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Unknown status,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2109325,AMG-191,1.0,Recruiting,MONDO_0015974,severe combined immunodeficiency,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL198362,RIVAROXABAN,4.0,,EFO_0000275,atrial fibrillation,,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL231779,APIXABAN,4.0,,EFO_0000275,atrial fibrillation,,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL2105682,EDOXABAN TOSYLATE,4.0,,EFO_0000275,atrial fibrillation,,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL512351,BETRIXABAN,4.0,,EFO_0004286,venous thromboembolism,,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL1269025,EDOXABAN,4.0,,HP_0004419,Recurrent thrombophlebitis,,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL4297951,COAGULATION FACTOR X HUMAN,4.0,,MONDO_0002247,factor X deficiency,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL1201554,ANTITHROMBIN ALFA,4.0,,HP_0001976,Reduced antithrombin III activity,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL3833393,EMICIZUMAB,4.0,"Active, not recruiting",MONDO_0010602,hemophilia A,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL4297768,IDRABIOTAPARINUX SODIUM,3.0,Terminated,EFO_0000275,atrial fibrillation,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL5314374,IDRAPARINUX SODIUM,3.0,Completed,EFO_0000275,atrial fibrillation,,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL5314801,IDRAPARINUX,3.0,Completed,EFO_0000275,atrial fibrillation,,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL3707365,BEMIPARIN,3.0,Unknown status,EFO_0001422,cirrhosis of liver,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL1922235,DAREXABAN,3.0,Completed,EFO_0004286,venous thromboembolism,,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL46618,OTAMIXABAN,3.0,Completed,EFO_0005672,acute coronary syndrome,,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,F10,ENSG00000126218,CHEMBL1095032,LETAXABAN,2.0,Completed,EFO_0005672,acute coronary syndrome,,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201657,HEPARIN SODIUM,4.0,,EFO_0000275,atrial fibrillation,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201476,ENOXAPARIN SODIUM,4.0,,EFO_0000612,myocardial infarction,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1200644,FONDAPARINUX SODIUM,4.0,,EFO_0000612,myocardial infarction,,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201414,TINZAPARIN SODIUM,4.0,Completed,EFO_0003907,deep vein thrombosis,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201460,DALTEPARIN SODIUM,4.0,,EFO_0004286,venous thromboembolism,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201202,FONDAPARINUX,4.0,,HP_0004419,Recurrent thrombophlebitis,,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201534,DANAPAROID SODIUM,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL4650299,HEPARIN,3.0,Completed,EFO_0000319,cardiovascular disease,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL2108080,PARNAPARIN SODIUM,3.0,Terminated,EFO_0000545,infertility,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL2108806,BEMIPARIN SODIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL2109204,NADROPARIN CALCIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL2108718,SEMULOPARIN SODIUM,3.0,Terminated,EFO_0004286,venous thromboembolism,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL4297754,FITUSIRAN,3.0,Completed,MONDO_0010602,hemophilia A,,
Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837,https://reactome.org/PathwayBrowser/#/R-HSA-140837,SERPINC1,ENSG00000117601,CHEMBL1201513,HEPARIN CALCIUM,2.0,Completed,EFO_1000954,habitual abortion,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL198362,RIVAROXABAN,4.0,,EFO_0000275,atrial fibrillation,,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL231779,APIXABAN,4.0,,EFO_0000275,atrial fibrillation,,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL2105682,EDOXABAN TOSYLATE,4.0,,EFO_0000275,atrial fibrillation,,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL512351,BETRIXABAN,4.0,,EFO_0004286,venous thromboembolism,,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL1269025,EDOXABAN,4.0,,HP_0004419,Recurrent thrombophlebitis,,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL4297951,COAGULATION FACTOR X HUMAN,4.0,,MONDO_0002247,factor X deficiency,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL1201554,ANTITHROMBIN ALFA,4.0,,HP_0001976,Reduced antithrombin III activity,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL3833393,EMICIZUMAB,4.0,"Active, not recruiting",MONDO_0010602,hemophilia A,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL4297768,IDRABIOTAPARINUX SODIUM,3.0,Terminated,EFO_0000275,atrial fibrillation,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL5314374,IDRAPARINUX SODIUM,3.0,Completed,EFO_0000275,atrial fibrillation,,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL5314801,IDRAPARINUX,3.0,Completed,EFO_0000275,atrial fibrillation,,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL3707365,BEMIPARIN,3.0,Unknown status,EFO_0001422,cirrhosis of liver,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL1922235,DAREXABAN,3.0,Completed,EFO_0004286,venous thromboembolism,,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL46618,OTAMIXABAN,3.0,Completed,EFO_0005672,acute coronary syndrome,,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,F10,ENSG00000126218,CHEMBL1095032,LETAXABAN,2.0,Completed,EFO_0005672,acute coronary syndrome,,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201657,HEPARIN SODIUM,4.0,,EFO_0000275,atrial fibrillation,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201476,ENOXAPARIN SODIUM,4.0,,EFO_0000612,myocardial infarction,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1200644,FONDAPARINUX SODIUM,4.0,,EFO_0000612,myocardial infarction,,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201414,TINZAPARIN SODIUM,4.0,Completed,EFO_0003907,deep vein thrombosis,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201460,DALTEPARIN SODIUM,4.0,,EFO_0004286,venous thromboembolism,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201202,FONDAPARINUX,4.0,,HP_0004419,Recurrent thrombophlebitis,,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201534,DANAPAROID SODIUM,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL4650299,HEPARIN,3.0,Completed,EFO_0000319,cardiovascular disease,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL2108080,PARNAPARIN SODIUM,3.0,Terminated,EFO_0000545,infertility,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL2108806,BEMIPARIN SODIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL2109204,NADROPARIN CALCIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL2108718,SEMULOPARIN SODIUM,3.0,Terminated,EFO_0004286,venous thromboembolism,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL4297754,FITUSIRAN,3.0,Completed,MONDO_0010602,hemophilia A,,
Common Pathway of Fibrin Clot Formation,R-HSA-140875,https://reactome.org/PathwayBrowser/#/R-HSA-140875,SERPINC1,ENSG00000117601,CHEMBL1201513,HEPARIN CALCIUM,2.0,Completed,EFO_1000954,habitual abortion,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL1743070,SILTUXIMAB,4.0,,EFO_0000540,immune system disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL1743071,SIRUKUMAB,3.0,,EFO_0000540,immune system disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL1743050,OLOKIZUMAB,3.0,,EFO_0000540,immune system disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL2109613,PF-04236921,2.0,Completed,EFO_0000384,Crohn's disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL2108589,CLAZAKIZUMAB,2.0,Terminated,EFO_0000384,Crohn's disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL2109614,MEDI-5117,1.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL4297732,ZILTIVEKIMAB,1.0,Completed,EFO_0003884,chronic kidney disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,IL6,ENSG00000136244,CHEMBL2109615,MRA 003 US,1.0,Completed,MONDO_0007915,systemic lupus erythematosus,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201657,HEPARIN SODIUM,4.0,,EFO_0000275,atrial fibrillation,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201476,ENOXAPARIN SODIUM,4.0,,EFO_0000612,myocardial infarction,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1200644,FONDAPARINUX SODIUM,4.0,,EFO_0000612,myocardial infarction,,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201414,TINZAPARIN SODIUM,4.0,Completed,EFO_0003907,deep vein thrombosis,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201460,DALTEPARIN SODIUM,4.0,,EFO_0004286,venous thromboembolism,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201202,FONDAPARINUX,4.0,,HP_0004419,Recurrent thrombophlebitis,,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201534,DANAPAROID SODIUM,4.0,,HP_0004419,Recurrent thrombophlebitis,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL4650299,HEPARIN,3.0,Completed,EFO_0000319,cardiovascular disease,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL2108080,PARNAPARIN SODIUM,3.0,Terminated,EFO_0000545,infertility,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL2108806,BEMIPARIN SODIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL2109204,NADROPARIN CALCIUM,3.0,Completed,EFO_0003907,deep vein thrombosis,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL2108718,SEMULOPARIN SODIUM,3.0,Terminated,EFO_0004286,venous thromboembolism,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL4297754,FITUSIRAN,3.0,Completed,MONDO_0010602,hemophilia A,,
Post-translational protein phosphorylation,R-HSA-8957275,https://reactome.org/PathwayBrowser/#/R-HSA-8957275,SERPINC1,ENSG00000117601,CHEMBL1201513,HEPARIN CALCIUM,2.0,Completed,EFO_1000954,habitual abortion,,
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1144,PRAVASTATIN,4.0,Completed,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1477,CERIVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1487,ATORVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1496,ROSUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL690,PRAVASTATIN SODIUM,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+]
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1064,SIMVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1201753,PITAVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL2220442,FLUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL503,LOVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL393220,ATORVASTATIN CALCIUM,4.0,,EFO_0000373,congestive heart failure,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1744447,ROSUVASTATIN CALCIUM,4.0,,EFO_0003914,atherosclerosis,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL2218894,FLUVASTATIN SODIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+]
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL1237061,PITAVASTATIN CALCIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2]
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL3989923,PITAVASTATIN MAGNESIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2]
Cholesterol biosynthesis,R-HSA-191273,https://reactome.org/PathwayBrowser/#/R-HSA-191273,HMGCR,ENSG00000113161,CHEMBL3989920,PITAVASTATIN SODIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1144,PRAVASTATIN,4.0,Completed,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1477,CERIVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1487,ATORVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1496,ROSUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL690,PRAVASTATIN SODIUM,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1064,SIMVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1201753,PITAVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL2220442,FLUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL503,LOVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL393220,ATORVASTATIN CALCIUM,4.0,,EFO_0000373,congestive heart failure,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1744447,ROSUVASTATIN CALCIUM,4.0,,EFO_0003914,atherosclerosis,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL2218894,FLUVASTATIN SODIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL1237061,PITAVASTATIN CALCIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL3989923,PITAVASTATIN MAGNESIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2]
PPARA activates gene expression,R-HSA-1989781,https://reactome.org/PathwayBrowser/#/R-HSA-1989781,HMGCR,ENSG00000113161,CHEMBL3989920,PITAVASTATIN SODIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1144,PRAVASTATIN,4.0,Completed,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1477,CERIVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1487,ATORVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1496,ROSUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL690,PRAVASTATIN SODIUM,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1064,SIMVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1201753,PITAVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL2220442,FLUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL503,LOVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL393220,ATORVASTATIN CALCIUM,4.0,,EFO_0000373,congestive heart failure,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1744447,ROSUVASTATIN CALCIUM,4.0,,EFO_0003914,atherosclerosis,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL2218894,FLUVASTATIN SODIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL1237061,PITAVASTATIN CALCIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL3989923,PITAVASTATIN MAGNESIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2]
Activation of gene expression by SREBF (SREBP),R-HSA-2426168,https://reactome.org/PathwayBrowser/#/R-HSA-2426168,HMGCR,ENSG00000113161,CHEMBL3989920,PITAVASTATIN SODIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1144,PRAVASTATIN,4.0,Completed,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1477,CERIVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1487,ATORVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1496,ROSUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL690,PRAVASTATIN SODIUM,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1064,SIMVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1201753,PITAVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL2220442,FLUVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL503,LOVASTATIN,4.0,,EFO_0000319,cardiovascular disease,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL393220,ATORVASTATIN CALCIUM,4.0,,EFO_0000373,congestive heart failure,,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1744447,ROSUVASTATIN CALCIUM,4.0,,EFO_0003914,atherosclerosis,,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL2218894,FLUVASTATIN SODIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL1237061,PITAVASTATIN CALCIUM,4.0,,EFO_0004911,familial hypercholesterolemia,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL3989923,PITAVASTATIN MAGNESIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2]
EGR2 and SOX10-mediated initiation of Schwann cell myelination,R-HSA-9619665,https://reactome.org/PathwayBrowser/#/R-HSA-9619665,HMGCR,ENSG00000113161,CHEMBL3989920,PITAVASTATIN SODIUM,4.0,,HP_0003119,Abnormal circulating lipid concentration,,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL779,TADALAFIL,4.0,,EFO_0000284,benign prostatic hyperplasia,,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL1737,SILDENAFIL CITRATE,4.0,,EFO_0001361,pulmonary arterial hypertension,,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL1339,VARDENAFIL HYDROCHLORIDE,4.0,,EFO_0004234,erectile dysfunction,,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL1520,VARDENAFIL,4.0,Completed,EFO_0004234,erectile dysfunction,,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL192,SILDENAFIL,4.0,Unknown status,EFO_0004234,erectile dysfunction,,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL1963681,AVANAFIL,4.0,,EFO_0004234,erectile dysfunction,,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL2103849,UDENAFIL,3.0,Unknown status,EFO_0001361,pulmonary arterial hypertension,,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL1928262,GISADENAFIL,2.0,Completed,EFO_0000284,benign prostatic hyperplasia,,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL4210847,PF-00489791,2.0,Completed,EFO_0000401,diabetic nephropathy,,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21
cGMP effects,R-HSA-418457,https://reactome.org/PathwayBrowser/#/R-HSA-418457,PDE5A,ENSG00000138735,CHEMBL591501,PF-03049423,2.0,Terminated,HP_0002140,Ischemic stroke,,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL6622,ISOSORBIDE DINITRATE,4.0,,EFO_0000319,cardiovascular disease,,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL730,NITROGLYCERIN,4.0,,EFO_0000319,cardiovascular disease,,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL1311,ISOSORBIDE MONONITRATE,4.0,,EFO_0000319,cardiovascular disease,,O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL4066936,VERICIGUAT,4.0,,EFO_0000319,cardiovascular disease,,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL466659,PENTAERYTHRITOL TETRANITRATE,4.0,,EFO_0000319,cardiovascular disease,,O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL136478,SODIUM NITROPRUSSIDE,4.0,,EFO_0000373,congestive heart failure,,
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL2097081,NITROPRUSSIDE,4.0,,EFO_0000537,hypertension,,
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL2107834,RIOCIGUAT,4.0,,EFO_0000537,hypertension,,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL1200689,NITRIC OXIDE,4.0,,EFO_0000684,respiratory system disease,,[N]=O
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL2107729,ATACIGUAT,2.0,Completed,EFO_0000266,aortic stenosis,,O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL1236936,CINACIGUAT,2.0,Terminated,EFO_0000373,congestive heart failure,,O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL4297214,PRALICIGUAT,2.0,Completed,EFO_0003144,heart failure,,OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL4650322,RUNCACIGUAT,2.0,Completed,EFO_0003770,diabetic retinopathy,,C[C@H]([C@H](C(=O)Nc1cc([C@@H](CC(=O)O)C2CC2)ccc1Cl)c1ccc(Cl)cc1)C(F)(F)F
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,GUCY1B1,ENSG00000061918,CHEMBL4297616,OLINCIGUAT,2.0,Terminated,HP_0002571,Achalasia,,NC(=O)[C@](O)(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)C(F)(F)F
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL779,TADALAFIL,4.0,,EFO_0000284,benign prostatic hyperplasia,,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL1737,SILDENAFIL CITRATE,4.0,,EFO_0001361,pulmonary arterial hypertension,,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL1339,VARDENAFIL HYDROCHLORIDE,4.0,,EFO_0004234,erectile dysfunction,,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL1520,VARDENAFIL,4.0,Completed,EFO_0004234,erectile dysfunction,,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL192,SILDENAFIL,4.0,Unknown status,EFO_0004234,erectile dysfunction,,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL1963681,AVANAFIL,4.0,,EFO_0004234,erectile dysfunction,,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL2103849,UDENAFIL,3.0,Unknown status,EFO_0001361,pulmonary arterial hypertension,,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL1928262,GISADENAFIL,2.0,Completed,EFO_0000284,benign prostatic hyperplasia,,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL4210847,PF-00489791,2.0,Completed,EFO_0000401,diabetic nephropathy,,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21
Smooth Muscle Contraction,R-HSA-445355,https://reactome.org/PathwayBrowser/#/R-HSA-445355,PDE5A,ENSG00000138735,CHEMBL591501,PF-03049423,2.0,Terminated,HP_0002140,Ischemic stroke,,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL779,TADALAFIL,4.0,,EFO_0000284,benign prostatic hyperplasia,,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL628,PENTOXIFYLLINE,4.0,,EFO_0000319,cardiovascular disease,,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL932,DIPYRIDAMOLE,4.0,,EFO_0000712,stroke,,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL1737,SILDENAFIL CITRATE,4.0,,EFO_0001361,pulmonary arterial hypertension,,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL1339,VARDENAFIL HYDROCHLORIDE,4.0,,EFO_0004234,erectile dysfunction,,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL1520,VARDENAFIL,4.0,Completed,EFO_0004234,erectile dysfunction,,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL192,SILDENAFIL,4.0,Unknown status,EFO_0004234,erectile dysfunction,,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL1963681,AVANAFIL,4.0,,EFO_0004234,erectile dysfunction,,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL2103849,UDENAFIL,3.0,Unknown status,EFO_0001361,pulmonary arterial hypertension,,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL19449,IBUDILAST,3.0,Recruiting,HP_0002196,Myelopathy,,CC(C)C(=O)c1c(C(C)C)nn2ccccc12
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL1928262,GISADENAFIL,2.0,Completed,EFO_0000284,benign prostatic hyperplasia,,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL4210847,PF-00489791,2.0,Completed,EFO_0000401,diabetic nephropathy,,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21
RHOBTB1 GTPase cycle,R-HSA-9013422,https://reactome.org/PathwayBrowser/#/R-HSA-9013422,PDE5A,ENSG00000138735,CHEMBL591501,PF-03049423,2.0,Terminated,HP_0002140,Ischemic stroke,,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK3,ENSG00000171303,CHEMBL1754,DOXAPRAM,4.0,,EFO_0000684,respiratory system disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK3,ENSG00000171303,CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,4.0,,EFO_0003818,lung disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK3,ENSG00000171303,CHEMBL1200694,SEVOFLURANE,3.0,Completed,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK3,ENSG00000171303,CHEMBL1256,ISOFLURANE,3.0,Recruiting,EFO_0009686,respiratory failure,,FC(F)OC(Cl)C(F)(F)F
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK3,ENSG00000171303,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK9,ENSG00000169427,CHEMBL1754,DOXAPRAM,4.0,,EFO_0000684,respiratory system disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK9,ENSG00000169427,CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,4.0,,EFO_0003818,lung disease,,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK9,ENSG00000169427,CHEMBL1200694,SEVOFLURANE,3.0,Not yet recruiting,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK9,ENSG00000169427,CHEMBL1256,ISOFLURANE,3.0,Withdrawn,HP_0000023,Inguinal hernia,,FC(F)OC(Cl)C(F)(F)F
TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316,https://reactome.org/PathwayBrowser/#/R-HSA-1299316,KCNK9,ENSG00000169427,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL1201828,ECULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL3989986,RAVULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL5315048,ZILUCOPLAN SODIUM,4.0,,EFO_0004991,Myasthenia gravis,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL4298086,POZELIMAB,4.0,,HP_0002243,Protein-losing enteropathy,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL2107979,PEXELIZUMAB,3.0,Completed,EFO_0001645,coronary artery disease,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL4298207,ZILUCOPLAN,3.0,Completed,EFO_0004991,Myasthenia gravis,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL4594316,CROVALIMAB,3.0,Withdrawn,EFO_0007292,Guillain-Barre syndrome,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL4297722,CEMDISIRAN,3.0,Recruiting,EFO_0004991,Myasthenia gravis,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL4297928,NOMACOPAN,3.0,Withdrawn,EFO_0007187,bullous pemphigoid,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL2109636,VILOBELIMAB,3.0,Recruiting,HP_0000999,Pyoderma,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL4298012,TESIDOLUMAB,2.0,Completed,EFO_0001365,age-related macular degeneration,,
Terminal pathway of complement,R-HSA-166665,https://reactome.org/PathwayBrowser/#/R-HSA-166665,C5,ENSG00000106804,CHEMBL3990025,OLENDALIZUMAB,2.0,Terminated,EFO_0002689,antiphospholipid syndrome,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL1201828,ECULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL3989986,RAVULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL5315048,ZILUCOPLAN SODIUM,4.0,,EFO_0004991,Myasthenia gravis,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL4298086,POZELIMAB,4.0,,HP_0002243,Protein-losing enteropathy,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL2107979,PEXELIZUMAB,3.0,Completed,EFO_0001645,coronary artery disease,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL4298207,ZILUCOPLAN,3.0,Completed,EFO_0004991,Myasthenia gravis,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL4594316,CROVALIMAB,3.0,Withdrawn,EFO_0007292,Guillain-Barre syndrome,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL4297722,CEMDISIRAN,3.0,Recruiting,EFO_0004991,Myasthenia gravis,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL4297928,NOMACOPAN,3.0,Withdrawn,EFO_0007187,bullous pemphigoid,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL2109636,VILOBELIMAB,3.0,Recruiting,HP_0000999,Pyoderma,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL4298012,TESIDOLUMAB,2.0,Completed,EFO_0001365,age-related macular degeneration,,
Activation of C3 and C5,R-HSA-174577,https://reactome.org/PathwayBrowser/#/R-HSA-174577,C5,ENSG00000106804,CHEMBL3990025,OLENDALIZUMAB,2.0,Terminated,EFO_0002689,antiphospholipid syndrome,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL1201828,ECULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL3989986,RAVULIZUMAB,4.0,,EFO_0000540,immune system disease,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL5315048,ZILUCOPLAN SODIUM,4.0,,EFO_0004991,Myasthenia gravis,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL4298086,POZELIMAB,4.0,,HP_0002243,Protein-losing enteropathy,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL2107979,PEXELIZUMAB,3.0,Completed,EFO_0001645,coronary artery disease,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL4298207,ZILUCOPLAN,3.0,Completed,EFO_0004991,Myasthenia gravis,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL4594316,CROVALIMAB,3.0,Withdrawn,EFO_0007292,Guillain-Barre syndrome,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL4297722,CEMDISIRAN,3.0,Recruiting,EFO_0004991,Myasthenia gravis,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL4297928,NOMACOPAN,3.0,Withdrawn,EFO_0007187,bullous pemphigoid,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL2109636,VILOBELIMAB,3.0,Recruiting,HP_0000999,Pyoderma,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL4298012,TESIDOLUMAB,2.0,Completed,EFO_0001365,age-related macular degeneration,,
Regulation of Complement cascade,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,C5,ENSG00000106804,CHEMBL3990025,OLENDALIZUMAB,2.0,Terminated,EFO_0002689,antiphospholipid syndrome,,
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL846,CALCITRIOL,4.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1200666,CALCIPOTRIENE,4.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1042,CHOLECALCIFEROL,4.0,Recruiting,EFO_0003882,osteoporosis,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1200622,PARICALCITOL,4.0,Terminated,EFO_0003884,chronic kidney disease,,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL3544909,CALCIFEDIOL,4.0,,EFO_0003884,chronic kidney disease,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1200810,DOXERCALCIFEROL,4.0,,EFO_0003884,chronic kidney disease,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1536,ERGOCALCIFEROL,4.0,,EFO_0009451,hypoparathyroidism,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1908376,SEOCALCITOL,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1040,CALCIFEDIOL ANHYDROUS,3.0,Completed,EFO_0000612,myocardial infarction,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL3989862,PEFCALCITOL,3.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL1601669,ALFACALCIDOL,3.0,Completed,EFO_0003882,osteoporosis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL4297608,ELDECALCITOL,3.0,Completed,EFO_0003882,osteoporosis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL2105107,INECALCITOL,2.0,Unknown status,EFO_0000222,acute myeloid leukemia,,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL2104955,BECOCALCIDIOL,2.0,Completed,EFO_0000676,psoriasis,,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL2105705,LUNACALCIPOL,2.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL605525,DP001,2.0,Completed,EFO_0003882,osteoporosis,,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O
Vitamin D (calciferol) metabolism,R-HSA-196791,https://reactome.org/PathwayBrowser/#/R-HSA-196791,VDR,ENSG00000111424,CHEMBL284121,ILX23-7553,1.0,Completed,EFO_0000616,neoplasm,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1082407,ENZALUTAMIDE,4.0,Unknown status,EFO_0000196,metastatic prostate cancer,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL806,FLUTAMIDE,4.0,,EFO_0000313,carcinoma,,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL409,BICALUTAMIDE,4.0,,EFO_0000313,carcinoma,,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL2107067,TESTOSTERONE UNDECANOATE,4.0,,EFO_0000616,neoplasm,,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1200335,TESTOSTERONE ENANTHATE,4.0,,EFO_0000616,neoplasm,,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1201101,TESTOSTERONE CYPIONATE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1274,NILUTAMIDE,4.0,,EFO_0000616,neoplasm,,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1445,FLUOXYMESTERONE,4.0,,EFO_0000616,neoplasm,,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL386630,TESTOSTERONE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL4297185,DAROLUTAMIDE,4.0,,EFO_0000616,neoplasm,,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL254328,ABIRATERONE,4.0,,EFO_0000616,neoplasm,,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3183409,APALUTAMIDE,4.0,"Active, not recruiting",EFO_0000673,prostate adenocarcinoma,,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1479,DANAZOL,4.0,,EFO_0001065,endometriosis,,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3590187,CLASCOTERONE,4.0,"Active, not recruiting",EFO_0003894,acne,,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1395,METHYLTESTOSTERONE,4.0,,MONDO_0002146,hypogonadism,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1200436,OXANDROLONE,3.0,Withdrawn,EFO_0000546,injury,,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL4594417,PRUXELUTAMIDE,3.0,Withdrawn,EFO_0000694,severe acute respiratory syndrome,,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1738889,ENOBOSARM,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL4650276,SHR3680,3.0,"Active, not recruiting",MONDO_0008315,prostate cancer,,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL2105738,GALETERONE,3.0,Terminated,MONDO_0008315,prostate cancer,,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL2079587,STANOZOLOL,2.0,Not yet recruiting,EFO_0000198,myelodysplastic syndrome,,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3545092,CR 1447,2.0,Terminated,EFO_0000304,breast adenocarcinoma,,
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3542265,LY2452473,2.0,Terminated,EFO_0000284,benign prostatic hyperplasia,,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3264610,SEVITERONEL,2.0,Terminated,EFO_0000616,neoplasm,,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1200946,NANDROLONE DECANOATE,2.0,Completed,EFO_0003964,hip fracture,,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL5170587,VK5211,2.0,Completed,EFO_0003964,hip fracture,,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL128748,DIMETHYLCURCUMIN,2.0,Completed,EFO_0003894,acne,,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3545333,MK-0773,2.0,Completed,EFO_1000653,sarcopenia,,
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3545174,GSK2881078,2.0,Completed,HP_0004326,Cachexia,,
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3545046,GSK2849466,1.0,Completed,HP_0004326,Cachexia,,
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL1170,TESTOSTERONE PROPIONATE,1.0,Suspended,EFO_1001271,Atrophic Vaginitis,,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL3545237,HE3235,1.0,Completed,MONDO_0008315,prostate cancer,,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL37676,APC-100,1.0,Unknown status,MONDO_0008315,prostate cancer,,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,AR,ENSG00000169083,CHEMBL2346976,AZD3514,1.0,Completed,MONDO_0008315,prostate cancer,,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL846,CALCITRIOL,4.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1200666,CALCIPOTRIENE,4.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1042,CHOLECALCIFEROL,4.0,Recruiting,EFO_0003882,osteoporosis,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1200622,PARICALCITOL,4.0,Terminated,EFO_0003884,chronic kidney disease,,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL3544909,CALCIFEDIOL,4.0,,EFO_0003884,chronic kidney disease,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1200810,DOXERCALCIFEROL,4.0,,EFO_0003884,chronic kidney disease,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1536,ERGOCALCIFEROL,4.0,,EFO_0009451,hypoparathyroidism,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1908376,SEOCALCITOL,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1040,CALCIFEDIOL ANHYDROUS,3.0,Completed,EFO_0000612,myocardial infarction,,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL3989862,PEFCALCITOL,3.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL1601669,ALFACALCIDOL,3.0,Completed,EFO_0003882,osteoporosis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL4297608,ELDECALCITOL,3.0,Completed,EFO_0003882,osteoporosis,,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL2105107,INECALCITOL,2.0,Unknown status,EFO_0000222,acute myeloid leukemia,,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL2104955,BECOCALCIDIOL,2.0,Completed,EFO_0000676,psoriasis,,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL2105705,LUNACALCIPOL,2.0,Completed,EFO_0000676,psoriasis,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL605525,DP001,2.0,Completed,EFO_0003882,osteoporosis,,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,VDR,ENSG00000111424,CHEMBL284121,ILX23-7553,1.0,Completed,EFO_0000616,neoplasm,,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Neurotransmitter receptors and postsynaptic signal transmission,R-HSA-112314,https://reactome.org/PathwayBrowser/#/R-HSA-112314,GLRA1,ENSG00000145888,CHEMBL1341,METHOXYFLURANE,4.0,Unknown status,EFO_0003843,pain,,COC(F)(F)C(Cl)Cl
Neurotransmitter receptors and postsynaptic signal transmission,R-HSA-112314,https://reactome.org/PathwayBrowser/#/R-HSA-112314,GLRA1,ENSG00000145888,CHEMBL1200694,SEVOFLURANE,3.0,Not yet recruiting,EFO_0000694,severe acute respiratory syndrome,,FCOC(C(F)(F)F)C(F)(F)F
Neurotransmitter receptors and postsynaptic signal transmission,R-HSA-112314,https://reactome.org/PathwayBrowser/#/R-HSA-112314,GLRA1,ENSG00000145888,CHEMBL1256,ISOFLURANE,3.0,Recruiting,EFO_0009686,respiratory failure,,FC(F)OC(Cl)C(F)(F)F
Neurotransmitter receptors and postsynaptic signal transmission,R-HSA-112314,https://reactome.org/PathwayBrowser/#/R-HSA-112314,GLRA1,ENSG00000145888,CHEMBL1200733,DESFLURANE,2.0,Completed,EFO_1002048,kidney failure,,FC(F)OC(F)C(F)(F)F
Xenobiotics,R-HSA-211981,https://reactome.org/PathwayBrowser/#/R-HSA-211981,CYP3A4,ENSG00000160868,CHEMBL163,RITONAVIR,4.0,Completed,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
Xenobiotics,R-HSA-211981,https://reactome.org/PathwayBrowser/#/R-HSA-211981,CYP3A4,ENSG00000160868,CHEMBL2095208,COBICISTAT,4.0,Not yet recruiting,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Xenobiotics,R-HSA-211981,https://reactome.org/PathwayBrowser/#/R-HSA-211981,CYP3A5,ENSG00000106258,CHEMBL2095208,COBICISTAT,4.0,,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Xenobiotics,R-HSA-211981,https://reactome.org/PathwayBrowser/#/R-HSA-211981,CYP3A5,ENSG00000106258,CHEMBL163,RITONAVIR,4.0,,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
Aflatoxin activation and detoxification,R-HSA-5423646,https://reactome.org/PathwayBrowser/#/R-HSA-5423646,CYP3A4,ENSG00000160868,CHEMBL163,RITONAVIR,4.0,Completed,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
Aflatoxin activation and detoxification,R-HSA-5423646,https://reactome.org/PathwayBrowser/#/R-HSA-5423646,CYP3A4,ENSG00000160868,CHEMBL2095208,COBICISTAT,4.0,Not yet recruiting,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Aflatoxin activation and detoxification,R-HSA-5423646,https://reactome.org/PathwayBrowser/#/R-HSA-5423646,CYP3A5,ENSG00000106258,CHEMBL2095208,COBICISTAT,4.0,,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Aflatoxin activation and detoxification,R-HSA-5423646,https://reactome.org/PathwayBrowser/#/R-HSA-5423646,CYP3A5,ENSG00000106258,CHEMBL163,RITONAVIR,4.0,,EFO_0000180,HIV-1 infection,,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL1076903,VARENICLINE,4.0,Terminated,EFO_0003768,nicotine dependence,,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL3,NICOTINE,4.0,,EFO_0003768,nicotine dependence,,CN1CCC[C@H]1c1cccnc1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL187927,DIANICLINE,3.0,Completed,EFO_0003768,nicotine dependence,,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL497939,CYTISINICLINE,3.0,,EFO_0003768,nicotine dependence,,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL5303393,VARENICLINE TARTRATE,3.0,Recruiting,EFO_0003768,nicotine dependence,,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL1201536,NICOTINE POLACRILEX,3.0,Completed,EFO_0003768,nicotine dependence,,
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL2103881,DEXMECAMYLAMINE,3.0,Completed,MONDO_0002009,major depressive disorder,,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL238465,SOFINICLINE,2.0,Completed,EFO_0000401,diabetic nephropathy,,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL4594254,SIMPINICLINE,2.0,Completed,EFO_0000555,irritable bowel syndrome,,C(=C/[C@H]1CCNC1)\c1cncnc1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL188462,ISPRONICLINE,2.0,Completed,EFO_0001072,memory impairment,,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL127071,POZANICLINE,2.0,Terminated,EFO_0003768,nicotine dependence,,Cc1ncccc1OC[C@@H]1CCCN1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL2179529,AZD1446,2.0,Completed,EFO_0003888,attention deficit hyperactivity disorder,,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL3707250,CP-601927,2.0,Terminated,MONDO_0002009,major depressive disorder,,
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587,https://reactome.org/PathwayBrowser/#/R-HSA-629587,CHRNB2,ENSG00000160716,CHEMBL504652,TC-2216,1.0,Completed,EFO_0005230,anxiety,,c1cncc(N2CCC3(CCCN3)C2)c1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL1076903,VARENICLINE,4.0,Terminated,EFO_0003768,nicotine dependence,,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL3,NICOTINE,4.0,,EFO_0003768,nicotine dependence,,CN1CCC[C@H]1c1cccnc1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL187927,DIANICLINE,3.0,Completed,EFO_0003768,nicotine dependence,,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL497939,CYTISINICLINE,3.0,,EFO_0003768,nicotine dependence,,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL5303393,VARENICLINE TARTRATE,3.0,Recruiting,EFO_0003768,nicotine dependence,,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL1201536,NICOTINE POLACRILEX,3.0,Completed,EFO_0003768,nicotine dependence,,
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL2103881,DEXMECAMYLAMINE,3.0,Completed,MONDO_0002009,major depressive disorder,,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL238465,SOFINICLINE,2.0,Completed,EFO_0000401,diabetic nephropathy,,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL4594254,SIMPINICLINE,2.0,Completed,EFO_0000555,irritable bowel syndrome,,C(=C/[C@H]1CCNC1)\c1cncnc1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL188462,ISPRONICLINE,2.0,Completed,EFO_0001072,memory impairment,,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL127071,POZANICLINE,2.0,Terminated,EFO_0003768,nicotine dependence,,Cc1ncccc1OC[C@@H]1CCCN1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL2179529,AZD1446,2.0,Completed,EFO_0003888,attention deficit hyperactivity disorder,,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL3707250,CP-601927,2.0,Terminated,MONDO_0002009,major depressive disorder,,
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,R-HSA-629594,https://reactome.org/PathwayBrowser/#/R-HSA-629594,CHRNB2,ENSG00000160716,CHEMBL504652,TC-2216,1.0,Completed,EFO_0005230,anxiety,,c1cncc(N2CCC3(CCCN3)C2)c1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL1076903,VARENICLINE,4.0,Terminated,EFO_0003768,nicotine dependence,,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL3,NICOTINE,4.0,,EFO_0003768,nicotine dependence,,CN1CCC[C@H]1c1cccnc1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL187927,DIANICLINE,3.0,Completed,EFO_0003768,nicotine dependence,,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL497939,CYTISINICLINE,3.0,,EFO_0003768,nicotine dependence,,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL5303393,VARENICLINE TARTRATE,3.0,Recruiting,EFO_0003768,nicotine dependence,,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL1201536,NICOTINE POLACRILEX,3.0,Completed,EFO_0003768,nicotine dependence,,
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL2103881,DEXMECAMYLAMINE,3.0,Completed,MONDO_0002009,major depressive disorder,,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL238465,SOFINICLINE,2.0,Completed,EFO_0000401,diabetic nephropathy,,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL4594254,SIMPINICLINE,2.0,Completed,EFO_0000555,irritable bowel syndrome,,C(=C/[C@H]1CCNC1)\c1cncnc1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL188462,ISPRONICLINE,2.0,Completed,EFO_0001072,memory impairment,,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL127071,POZANICLINE,2.0,Terminated,EFO_0003768,nicotine dependence,,Cc1ncccc1OC[C@@H]1CCCN1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL2179529,AZD1446,2.0,Completed,EFO_0003888,attention deficit hyperactivity disorder,,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL3707250,CP-601927,2.0,Terminated,MONDO_0002009,major depressive disorder,,
Highly calcium permeable nicotinic acetylcholine receptors,R-HSA-629597,https://reactome.org/PathwayBrowser/#/R-HSA-629597,CHRNB2,ENSG00000160716,CHEMBL504652,TC-2216,1.0,Completed,EFO_0005230,anxiety,,c1cncc(N2CCC3(CCCN3)C2)c1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
Circadian Clock,,,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
PTK6 Expression,R-HSA-8849473,https://reactome.org/PathwayBrowser/#/R-HSA-8849473,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,GSK3B,ENSG00000082701,CHEMBL1200826,LITHIUM CARBONATE,4.0,,EFO_0009963,bipolar I disorder,,O=C([O-])[O-].[Li+].[Li+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,GSK3B,ENSG00000082701,CHEMBL2103738,LITHIUM CITRATE,4.0,,EFO_0009963,bipolar I disorder,,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,GSK3B,ENSG00000082701,CHEMBL362558,LY-2090314,2.0,Completed,EFO_0000565,leukemia,,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,GSK3B,ENSG00000082701,CHEMBL483465,ELRAGLUSIB,2.0,"Active, not recruiting",EFO_0000691,sarcoma,,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,GSK3B,ENSG00000082701,CHEMBL3545157,TIDEGLUSIB,2.0,Completed,EFO_0003756,autism spectrum disorder,,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
Regulation of RUNX2 expression and activity,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",R-HSA-9615017,https://reactome.org/PathwayBrowser/#/R-HSA-9615017,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201109,DESONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL131,PREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1473,FLUTICASONE PROPIONATE,4.0,,EFO_0000274,atopic eczema,,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1650,CORTISONE ACETATE,4.0,,EFO_0000274,atopic eczema,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1683,HYDROCORTISONE BUTYRATE,4.0,,EFO_0000274,atopic eczema,,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL389621,HYDROCORTISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL635,PREDNISONE,4.0,,EFO_0000274,atopic eczema,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL650,METHYLPREDNISOLONE,4.0,,EFO_0000274,atopic eczema,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1370,BUDESONIDE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1676,FLUTICASONE FUROATE,4.0,,EFO_0000341,chronic obstructive pulmonary disease,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL384467,DEXAMETHASONE,4.0,,EFO_0000274,atopic eczema,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL989,FLUOCINOLONE ACETONIDE,4.0,,EFO_0000274,atopic eczema,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200384,BETAMETHASONE DIPROPIONATE,4.0,,EFO_0000544,infection,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1504,TRIAMCINOLONE ACETONIDE,4.0,,EFO_0000546,injury,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,4.0,,EFO_0000574,lymphoma,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1364144,METHYLPREDNISOLONE ACETATE,4.0,,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1766,DESOXIMETASONE,4.0,,EFO_0000676,psoriasis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1159650,CLOBETASOL PROPIONATE,4.0,,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200908,HALOBETASOL PROPIONATE,4.0,Terminated,EFO_0000676,psoriasis,,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1091,HYDROCORTISONE ACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200386,PREDNICARBATE,4.0,,EFO_0000701,skin disease,,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200545,DIFLORASONE DIACETATE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200953,HYDROCORTISONE PROBUTATE,4.0,,EFO_0000701,skin disease,,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,4.0,,EFO_0000701,skin disease,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1497,BETAMETHASONE VALERATE,4.0,,EFO_0000701,skin disease,,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1501,FLUOCINONIDE,4.0,,EFO_0000701,skin disease,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1161,MOMETASONE FUROATE,4.0,,EFO_0000701,skin disease,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200845,HALCINONIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201012,FLURANDRENOLIDE,4.0,,EFO_0000701,skin disease,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1451,TRIAMCINOLONE,4.0,,EFO_0000701,skin disease,,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200538,BETAMETHASONE ACETATE,4.0,,EFO_0000729,ulcerative colitis,,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,4.0,,EFO_0000729,ulcerative colitis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1276308,MIFEPRISTONE,4.0,,EFO_0003099,Cushing syndrome,,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200600,FLUOROMETHOLONE,4.0,,EFO_0003894,acne,,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200617,RIMEXOLONE,4.0,,EFO_0005752,eye inflammation,,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201173,MEDRYSONE,4.0,,EFO_0005752,eye inflammation,,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL632,BETAMETHASONE,4.0,,EFO_0005752,eye inflammation,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200865,LOTEPREDNOL ETABONATE,4.0,,EFO_0007141,allergic conjunctivitis,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,4.0,Completed,EFO_0003956,seasonal allergic rhinitis,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL2040682,CICLESONIDE,4.0,,EFO_0003956,seasonal allergic rhinitis,,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201749,DIFLUPREDNATE,4.0,,EFO_1000811,anterior uveitis,,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1152,PREDNISOLONE ACETATE,4.0,,EFO_0007141,allergic conjunctivitis,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1512,FLUNISOLIDE,4.0,,EFO_0008521,rhinitis,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,4.0,,MONDO_0004979,asthma,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,4.0,Unknown status,MONDO_0005178,osteoarthritis,,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201891,DEFLAZACORT,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL3707311,VAMOROLONE,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1530428,DEXAMETHASONE ACETATE,3.0,Unknown status,EFO_0000565,leukemia,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL139835,CYPROTERONE ACETATE,3.0,Completed,EFO_0000673,prostate adenocarcinoma,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL4068611,RELACORILANT,3.0,Completed,EFO_0003099,Cushing syndrome,,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,3.0,Completed,EFO_0006834,septic shock,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,3.0,Completed,EFO_1000811,anterior uveitis,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,3.0,Unknown status,EFO_0007308,Herpes simplex virus keratitis,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,3.0,Terminated,EFO_1001097,periarthritis,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL2103876,MAPRACORAT,3.0,Completed,MONDO_0005129,cataract,,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL4072756,AZD-5423,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL3545391,ORG-34517,2.0,Completed,EFO_0000677,mental or behavioural disorder,,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL4297572,ABBV-3373,2.0,Completed,EFO_0000685,rheumatoid arthritis,,
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL3137316,FOSDAGROCORAT,2.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1201148,MEPREDNISONE,2.0,Completed,EFO_0000756,melanoma,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL2105842,CORTIVAZOL,2.0,Completed,EFO_0003843,pain,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL3666807,VELSECORAT,2.0,Completed,MONDO_0004979,asthma,,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2
Regulation of NPAS4 gene transcription,R-HSA-9768777,https://reactome.org/PathwayBrowser/#/R-HSA-9768777,NR3C1,ENSG00000113580,CHEMBL1549,HYDROCORTISONE CYPIONATE,2.0,Completed,MONDO_0015129,chronic primary adrenal insufficiency,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2,ENSG00000164400,CHEMBL3039547,PEXASTIMOGENE DEVACIREPVEC,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2,ENSG00000164400,CHEMBL2109433,OTILIMAB,3.0,Completed,EFO_0000685,rheumatoid arthritis,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2,ENSG00000164400,CHEMBL3707325,LENZILUMAB,3.0,"Active, not recruiting",EFO_0003106,pneumonia,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2,ENSG00000164400,CHEMBL1743044,NAMILUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2,ENSG00000164400,CHEMBL4650518,PLONMARLIMAB,2.0,Completed,MONDO_0100096,COVID-19,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2,ENSG00000164400,CHEMBL2109430,GIMSILUMAB,2.0,Completed,MONDO_0100096,COVID-19,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000540,immune system disease,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,4.0,,EFO_0000540,immune system disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,Enrolling by invitation,EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,Recruiting,EFO_0000519,glioblastoma multiforme,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Completed,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Completed,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
